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ABSTRACT 
Skeletal muscle insulin resistance is a major characteristic of obesity and type 2 
diabetes. Although obesity-mediated inflammation is causally associated with insulin 
resistance, the underlying mechanism is unclear. Our lab and others have shown that a 
chronic low-grade inflammation takes place in skeletal muscles during diet-induced 
obesity, as evidenced by increased macrophage markers and pro-inflammatory cytokine 
levels. Interleukin (IL)-10 is a Th2-type cytokine that inhibits the synthesis and activity of 
pro-inflammatory cytokines and counteracts the Toll-like receptor-mediated inflammation. 
Our lab has previously demonstrated the preventive role of IL-10 against insulin resistance. 
Here, I have analyzed the effects of IL-10 on the skeletal muscle glucose metabolism and 
myogenesis in three different insulin resistant states (high fat diet-induced, leptin-
deficiency-induced and aging-induced). The first model involved long-term (16 weeks) 
high-fat diet (HFD) feeding that resulted in markedly obese and hyperglycemic mice, 
representative of obese type 2 diabetic subjects. In mice overexpressing IL-10 specifically 
in the skeletal muscle (MIL10), we observed improved whole-body and skeletal muscle 
insulin sensitivity as compared to wild-types after long-term high fat diet feeding. The 
improved insulin sensitivity in the skeletal muscle was due to increased Akt signaling and 
decreased muscle inflammation. Leptin is an important adipocyte-derived hormone that is 
elevated in obesity, and it regulates numerous physiological functions including the energy 
balance and inflammation. Thus, my second model examined the effects of muscle-specific 
overexpression of IL-10 on glucose metabolism in the hyperphagic, leptin-deficient ob/ob 
mice. We detected improved whole-body insulin sensitivity compared to the control mice. 
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My third model examined the effects of increased IL-10 expression using MIL10 mice 
during aging-induced insulin resistance. In 18-month old MIL10 mice, we found enhanced 
whole-body and skeletal muscle insulin sensitivity due to improved insulin signaling and 
decreased muscle inflammation as compared to wild-type mice. Last, to test whether direct 
signaling of IL-10 on skeletal muscle is responsible for the beneficial effects of IL-10 on 
muscle glucose metabolism, I generated mice lacking IL-10 receptor 1 type chain 
selectively in skeletal muscle (M-IL10R-/-). We observed more prominent muscle 
inflammation and whole-body insulin resistance in HFD-fed M-IL10R-/- mice as compared 
to wild-type mice. Interestingly, when studying insulin resistance in the IL-10 transgenic 
mouse models, we identified a consistent increased lean mass phenotype, and conversely 
decreased lean mass in the HFD-fed M-IL10R-/- mice. Quantitative RT-PCR on HFD-fed 
MIL10 group muscles to measure myogenesis-related gene expression identified a 
correlation between lean mass and both IL-10 and MyoD mRNA expression levels.  In 
support of this, I showed that IL-10 caused an increase in in vitro cultured myoblast 
proliferation rates. Together, these results highlight the potential benefits of IL-10 
expression not only in muscle glucose metabolism but also in maintaining muscle mass 
during insulin resistant states. Overall, these results demonstrate that selective expression 
of IL-10 in skeletal muscle suppresses inflammation, improves glucose metabolism and 
muscle growth in obese and aging mice, and further establishes that these effects are at 
least partially mediated by direct activation of IL-10 signaling in skeletal muscle. 
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1.1 Insulin Resistance: 
 1.1.1 Obesity, Type 2 Diabetes and Insulin Resistance 
Excess body weight poses a risk for developing serious metabolic diseases such as 
type 2 diabetes, cardiovascular disease and cancer [1]. Unfortunately, the obesity 
prevalence in the United States has increased by 2-fold in the last 30 years since the 1980s, 
with the USA being the country with the highest body mass index average among 
developed countries [1]. Western diet, physical inactivity and irregular eating habits due to 
the modern lifestyle are fueling the spread of obesity across the nation [2]. Although many 
precautions are taken to promote healthy lifestyle changes, obesity still stands out as the 
most prevalent health problem in the population affecting one out of every three people 
[1]. 
Type 2 diabetes is a metabolic disease created by the failure of a highly-regulated 
multi-organ network to sustain circulating glucose at euglycemic levels. It is characterized 
by obesity, impaired insulin action, insulin secretory dysfunction, and increased 
endogenous glucose production [3]. Some studies suggest the decreased insulin action is 
the initial step in type 2 diabetes development [4-6], whereas others propose that β cell 
dysfunction as the primary factor [7-9]. Both are important for the early pathogenesis of 
type 2 diabetes [3, 10]. Genetic susceptibility and family history are also important factors 
in developing type 2 diabetes [11-13]. 
The most noticeable problems leading to type 2 diabetes are pancreatic β cell failure 
and liver, adipose tissue and muscle insulin resistance [14]. β cells are responsible for the 
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release of insulin that stimulates glucose uptake into metabolic organs, and the loss of β 
cell functionality is a major factor in the pathogenesis of type 2 diabetes [15]. Insulin 
resistance, defined as decreased response to insulin-stimulated glucose uptake in tissues 
[16], develops prior to type 2 diabetes. Insulin induces glucose uptake into skeletal muscle 
and adipose tissue [17] and acts on the liver to suppress hepatic glucose production [18]. 
Adipose tissue, skeletal muscle and liver sensitivity to insulin diminishes as insulin 
resistance develops. Since glucose uptake into muscle and fat decreases and liver glucose 
output increases due to insufficient suppression of glycogen breakdown and 
gluconeogenesis, glucose levels rise in the circulation [17]. 
β cells can respond to the decreased sensitivity of insulin in metabolic tissues by 
increasing β cell mass to raise insulin levels [19, 20]. β cell proliferation was also detected 
in mice even before the onset of insulin resistance [21], and researchers showed that obesity 
can result in a 50% increase in β cell mass [22]. Hyperinsulinemia due to the β cell mass 
increase can maintain physiologic glucose levels initially, however prediabetes or type 2 
diabetes eventually develops in part due to the inability to maintain compensatory insulin 
levels because of insufficient pancreatic β cell mass and activity [23, 24].  
Obesity is a main factor initiating insulin resistance and type 2 diabetes [25]. 
Increased circulating free fatty acids (FFA), adipose tissue dysfunction and inflammation, 
and impaired insulin signaling in muscle during obesity all lead to type 2 diabetes [26]. 
Abdominal fat deposition is a strong hallmark of these diseases [27] along with the low-
grade chronic inflammation linked to insulin resistance and type 2 diabetes [28-30]. Stress 
kinase pathways like Jun N-terminal kinase (JNK), nuclear factor kappa B (NFB), IκB β 
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kinase (IKKβ) play important roles in inflammation-mediated suppression of insulin 
signaling, mainly by serine phosphorylation of Akt [31-33]. Other stress factors such as 
endoplasmic reticulum (ER) stress [34-36], induction of inducible nitric oxide synthase 
(iNOS) [37], and reactive oxygen species (ROS) are also associated with type 2 diabetes 
[38, 39]. 
It is projected that by 2030, 5 out of every 100 people will develop type 2 diabetes 
[40]. It is indisputable that diabetes is standing as an urgent priority, and growing like an 
epidemic costing almost $250  billion yearly in the USA [16, 41]. Increasing prevalence of 
diabetes is also a global threat accounting for 2 million deaths every year and, it is the 7th 
leading cause of disability in the world [42, 43]. Unless necessary actions are taken to 
prevent and treat it, worldwide morbidity and mortality rates of diabetes will become a 
great burden in the near future. 
 1.1.2 Aging and Insulin Resistance  
Aging is related to peripheral insulin resistance as evident from higher type 2 
diabetes rates in the elderly [44-47]. This insulin resistance in the periphery is correlated 
with a gradual increase in total adiposity with age [48]. Aging is associated with abdominal 
increased adipose tissue and decreased lean mass phenotype [49]. Abdominal fat 
accumulation and physical inactivity coming with old age are thought to be the main 
reasons causing insulin resistance in old age [45, 50-52]. Research results confirmed that 
obese, sarcopenic old subjects were found to develop more profound insulin resistance 
[49]. Moreover, in a study where visceral fat was removed from aging rats, they found that 
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insulin resistance was improved [53]. However, there are studies supporting that insulin 
resistance during aging is independent of total obesity [54].  
Insulin resistance in the elderly was also found to be associated with reduced 
mitochondrial function due ectopic fat accumulation in muscle and liver [47]. Yet, 
increased obesity and inflammation during aging were still suggested to be the most 
important factors promoting the insulin resistance [55]. 
Since insulin resistance and type 2 diabetes are more frequent in elders and are 
associated with frailty, they pose a risk for the healthy course of life. As lifespan is 
increasing with recent advancements in healthcare and science, it is essential that we direct 
resources to the welfare of the old population. 
 1.1.3 Chronic Inflammation in Insulin Resistance 
The preventive effects of anti-inflammatory agents against insulin resistance was 
reported many times in history, yet the mechanism was unclear until recently [56-58]. In 
the early 90’s researchers found the link between adipose tissue inflammation, obesity, and 
insulin resistance [59]. Hotamisligil et. al showed that inflammatory tumor necrosis factor 
alpha (TNFα) is synthesized from adipose tissues of obese subjects resulting in insulin 
resistance [60]. Not long after, the relationship between inflammation and insulin 
resistance was widely accepted in the field as a trending topic [61-65].   
Systemic inflammation was tied to insulin resistance in large population studies [66-
68]. Increased inflammatory markers from type 2 diabetic and insulin resistant patients 
were among the typical findings. Also, disruption of the IKKβ, JNK pathways, that are 
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essential for mediating the inflammatory response in tissues, increased insulin sensitivity 
in mice and human [33, 69-73]. Cellular stresses like ER stress, ROS induction were all 
found to be associated with inflammation, triggering the insulin resistance [36, 74]. 
However, inflammation occurring during obesity is different from the traditional large-
scale inflammatory response with highly and acutely elevated inflammatory cytokines 
upon stimulation. Obesity-induced inflammation is a low-scale chronic response referred 
to as ‘metaflammation’ with constant and modest amounts of released cytokines activating 
different mechanisms [65, 66, 75, 76]. This subclinical inflammation can precede type 2 
diabetes [67, 68]. 
The link between inflammation and insulin resistance was first discovered in adipose 
tissue, therefore, most of the research was based on adipose tissue inflammation. 
Researchers reported increased macrophage infiltration and proliferation, cytokine and 
chemokine expression in adipose tissues of insulin-resistant mice [59, 60, 77-80]. 
Macrophages were defined as key players in inflammation-induced insulin resistance in 
obesity [81].  Other immune cells like natural killer cells and mast cells were also found to 
be elevated in obese patients [82, 83]. Inflammation became a much-studied link between 
obesity and insulin resistance that was under the spotlight for quite a while. Yet, obesity 
does not induce insulin resistance only in adipose tissue. Other metabolic tissues such as 
skeletal muscle, liver and heart also become insulin resistant during obesity [84]. Even 
though some researchers believe that insulin resistance in these metabolic tissues is 
triggered indirectly by adipokines released to the circulation and ectopic fat surrounding 
these tissues [64, 85-88], there is evidence that skeletal muscle and liver themselves 
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develop increased inflammation when mice are fed with HFD [89-94]. The latest view is 
the whole organism including adipose tissue, skeletal muscle, liver and even intestines 
cross-talk with each other during this chronic inflammation [95]. Overall, obesity seems to 
generate a mild inflammation in all metabolic tissues resulting in pronounced insulin 
resistance in the end. 
Considering inflammation is defined to be the link between obesity and insulin 
resistance, anti-inflammatory therapies in the treatment of these conditions gain 
importance. Generating monoclonal antibodies against inflammatory cytokines, or 
working on natural anti-inflammatory cytokines to restore the balance between pro-
inflammatory and anti-inflammatory mediators are becoming common strategies.  More 
studies are revealing the mechanisms connecting the immune system to insulin resistance 
every day, that will render it possible to develop strategies for severe outcomes in the near 
future. 
1.2 Skeletal Muscle 
1.2.1 Skeletal Muscle as a Metabolic Tissue 
Approximately 40% of our body mass consists of skeletal muscle [96]. Skeletal 
muscle is the largest metabolic tissue and is mainly responsible for glucose homeostasis in 
the body. Skeletal muscle by itself is the major site for glucose uptake after a meal, taking 
up ~80% of the insulin-stimulated glucose uptake after eating [97]. Skeletal muscle 
maintains glucose uptake by both insulin-dependent and insulin-independent mechanisms, 
and requires a significant proportion of energy, being responsible for physical activity [98]. 
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In the post-absorptive state, insulin signaling stimulates the glucose transporters for 
glucose uptake, whereas during exercise, contractions increase glucose uptake by 
facilitated diffusion [99]. Intense exercise can also increase muscle blood flow up to 20-
fold, promoting the glucose delivery for tissue uptake [100]. The glucose uptake during 
contractions, and the increased muscle glucose metabolism and insulin sensitivity after 
exercise do not require insulin [101]. Under euglycemic conditions, majority of non-insulin 
dependent glucose uptake (NIDGU) occurs in non-muscle tissues [98]. On the other hand, 
researchers stated that during hyperglycemia, half of the total glucose uptake in the skeletal 
muscle is non-insulin dependent [98] and hyperglycemia can increase GLUT4 
translocation to the membrane [102]. Therefore, both insulin-dependent and insulin-
independent glucose uptake are important for skeletal muscle metabolism. 
Blood flow into skeletal muscle in resting state is only ~0.04 ml/min per gram tissue, 
therefore blood flow into skeletal muscle is a rate-determining state for the delivery of 
insulin and glucose [103]. Insulin, by interacting with endothelium, can vasodilate skeletal 
muscle vasculature and recruit capillaries to increase blood flow and increase glucose 
uptake [103, 104]. Thus, insulin can control its own delivery to the muscle by acting on the 
vasculature [105]. This vasodilating action which provides more blood flow is impaired 
during insulin resistance. Insulin passes across the endothelial cells via insulin receptor 
signaling, and thereby promotes its own transfer to reach to the muscle fibers [106, 107]. 
Insulin is concentrated at endothelial cells for its trans-endothelial transport [108]. 
Transport of insulin across the vascular wall to muscle interstitium is suggested to be a rate 
limiting step [109], and only 50% of the plasma insulin was measured to reach muscle 
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interstitium [110]. Insulin reaches the muscle fibers after passing through the endothelial 
cell barrier. 
Obesity results from excess calorie intake and lack of physical activity. When we 
provide more fuel into muscles than it needs and muscles cannot consume it; the energy 
balance is disturbed resulting in obesity and diabetes. Skeletal muscle regulates euglycemia 
by cross-talking with liver and adipose tissue. Therefore, for keeping healthy metabolic 
state, maintaining homeostasis in insulin-responsive tissues is crucial. 
Skeletal muscle uses glucose and FFA as energy fuels. During the fasting state FFA 
is the primary fuel, whereas glucose uptake is the main source in the post-absorptive state 
[111]. Glucose uptake in tissues is facilitated mainly by GLUT4 and GLUT1 [112]. 
GLUT4 is the most dominant form in the skeletal muscle and is responsible for transferring 
glucose inside the fibers to be metabolized [113, 114]. Upon food intake insulin is secreted 
from β cells and travels through the circulation to reach skeletal muscles. Insulin then binds 
to insulin receptors on the fiber surface and activates intrinsic tyrosine kinase to auto-
phosphorylate insulin receptor [113]. Then tyrosines are recognized by phosphotyrosine 
binding domains of insulin receptor substrate (IRS) proteins [115]. When insulin receptor 
phosphorylates tyrosine residues on IRS-I, it generates docking sites for the Src homology 
2 (SH2) domains of the phosphatidylinositol 3-kinase (PI3K) [116]. Then PI3K converts 
phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) which activates PIP3 dependent kinase (PDK1), the serine kinase that activates Akt 
[117]. Activated Akt inactivates glycogen synthase kinase 3 (GSK3). Inactivation of GSK3 
promotes glycogen synthesis. Akt substrate of 160 kDa (AS160) has binding sites for Rab-
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GTPase activating proteins which load Rab proteins with guanosine triphosphate (GTP) 
[118]. GLUT4 glucose transporters are usually found inside the cytoplasm attached to 
vesicles. Rab proteins are responsible for membrane trafficking [119]. They help to fuse 
these vesicles with cell membrane translocating more GLUT4 to the membrane [118]. 
Increased GLUT4 numbers in the muscle membrane in return increases glucose uptake in 
the skeletal muscle (Fig. 1.1). After uptake into muscles by GLUT4, glucose is 
phosphorylated by hexokinase, and it is either turned into glycogen to be stored or enters 
the glycolytic pathway. Therefore, insulin signaling pathway is a fundamental and complex 
process for providing glucose supply to the resting muscles.  
1.2.2 Skeletal Muscle Insulin Resistance 
Skeletal muscle is a very large insulin-responsive tissue. Along with the liver and 
adipose tissue, the glucose metabolism in skeletal muscle is important for the whole-body 
glucose homeostasis. Researchers define skeletal muscle insulin resistance as one of the 
major defects in type 2 diabetes, along with the insulin deficiency due to β cell failure [120, 
121]. Studies have revealed that it can precede hyperglycemia [122, 123] and impairment 
of muscle glycogen synthesis pathway was found to be an important step during diabetes 
[124]. Researchers analyzed glucose metabolism of normoglycemic subjects with diabetic 
parents and found that hyperinsulinemia due to β cell activity, muscle insulin resistance, 
and impaired glucose oxidation were already present before the onset of diabetes [66]. In 
another study, researchers found that in the offspring of diabetic parents there was a 50% 
reduction in total glucose metabolism, a 70% reduction in muscle glycogen synthesis and 
a 40% reduction in muscle glucose-6-phosphate (G6P) concentration like their diabetic 
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parents [125]. These results suggested that muscle glucose transport, metabolism, and 
glycogen synthesis impairments are some of the fundamental steps for the onset of type 2 
diabetes along with other factors.  
Skeletal muscle insulin resistance can occur due to impairment of the insulin 
signaling pathway. When Insulin-IRS-Akt cascade is impaired, the muscle becomes insulin 
resistant [126, 127]. An 80% reduction in IRS-I phosphorylation and 90% reduction in 
PI3K activation was detected in obese, diabetic mouse muscles [128]. Tyrosine 
phosphorylation of IRS-I is one of the central switches controlling insulin signaling. Stress 
kinases like IKKβ, NF-κB and JNK are known to cause serine phosphorylation of IRS-I 
which inhibits its phosphorylation at tyrosine residues [129, 130]. These kinases can be 
activated following metabolic stress or inflammation [131]. Researchers in collaboration 
with our lab showed that inhibition of JNK signaling in skeletal muscle improves insulin 
sensitivity of skeletal muscle without affecting obesity [132]. 
 Skeletal muscle insulin resistance can be caused by obesity, since weight loss can 
restore muscle insulin sensitivity in mice [133, 134]. Elevated fatty acids or lipid 
intermediates during obesity were also found to be linked to muscle insulin resistance 
[135], mostly through protein kinase C (PKC) which inhibits IRS-I, PI3K and Akt signaling 
[136-138]. Especially when uptaken fatty acids are not metabolized by β oxidation, they 
accumulate as diacylglycerol (DAG) and ceramides which can inhibit insulin signaling 
[139, 140]. There is also in vitro evidence that fatty acid treated macrophages induce 
insulin resistance in myocytes [141]. High plasma FFA concentrations due to HFD are also 
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Figure 1.1 Insulin signaling/glucose uptake pathway in skeletal muscle fibers. 
 
 
 
 
 
 
 
13 
 
suggested to cause toxic intramyocellular lipid accumulation, activation of inflammatory 
pathways, increase in ROS, inducible nitric oxide synthase (iNOS) and mitochondrial 
dysfunction which may result in insulin resistance [142]. However, abundant 
intramyocellular lipid levels in insulin sensitive endurance athletes suggest that increased 
fatty acids are not the major factor contributing to muscle insulin resistance [143, 144]. 
Also, systemic effects of obesity like inflammation or fatty acids seem to be necessary for 
skeletal muscle insulin resistance since when isolated myocytes from obese patients are 
cultured without stimulation they don’t show insulin resistance [145]. In the bigger picture, 
excess energy intake seems to result in elevated fatty acids, oxidative stress and 
inflammatory cytokines which synergistically increase lipid accumulation and insulin 
resistance in skeletal muscle. Identifying the exact molecular mechanisms resulting in 
skeletal muscle insulin resistance in obesity is not accomplished yet and requires further 
investigation. 
1.2.3 Skeletal Muscle Inflammation 
Chronic inflammation in metabolic tissues during insulin resistance was reported 
numerous times in the field. Either through increased immune cells and inflammatory 
cytokines in muscle or, through FFAs in circulation [146]; inflammation is a major 
pathway resulting in skeletal muscle insulin resistance [147].  
When researchers are investigating the relationship between inflammation and 
insulin resistance, the attention is usually focused on the adipose tissue inflammation [86]. 
However, there is also convincing data about the role of skeletal muscle inflammation 
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during diabetes. Skeletal muscle is a secretory organ that can release cytokines called 
myokines [148, 149]. TNFα, IL-6 and IL-10 were shown to have all direct effects on 
skeletal muscle [147]. In addition to the increased circulating levels of inflammatory 
cytokines released from adipose tissue during obesity, the muscle itself can also release 
inflammatory cytokines in response to stress [150-152].  
The link between inflammation and skeletal muscle insulin resistance is reflected 
in a series of observations: infiltration of inflammatory cells (macrophages, natural killer 
cells, dendritic cell, T cells) into skeletal muscles of type 2 diabetes patients and insulin 
resistant-obese mice [93, 153-158]; inflammatory cytokines overproduced by insulin 
resistant muscles from obese humans [94, 153]; inflammatory cytokines released from 
myocyte cultures of diabetic patients [159]; ability of muscles to generate and release 
inflammatory cytokines [160, 161]; ability of myocytes to recruit leukocytes from the 
blood stream [162]; expression of immune system components like Toll-like receptors 
(TLR) by muscle fibers [150, 163]; inflammatory chemokines triggering insulin resistance 
in cultured myoblasts [164]; and induction of skeletal muscle insulin resistance by cytokine 
infusion into humans [165, 166].  Pro-inflammatory cytokines TNFα, IL-6, IL-1 and 
monocyte chemoattractant protein-1 (MCP-1), were all shown to exert adverse effects on 
skeletal muscle insulin signaling [166]. Furthermore, pro-inflammatory cytokine TNFα 
resulted in insulin resistance in myocytes [167] and, was shown to be directly synthesized 
by the muscle [94]. It was also synthesized 4-fold higher in insulin resistant subjects’ 
muscles than controls. Macrophage numbers were also reported to be higher in skeletal 
muscles of obese patients [168]; and inflammatory receptor TLR4 and JNK proteins were 
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shown to be more abundant in the skeletal muscles of type 2 diabetic subjects [169, 170].  
Another study investigating the muscle inflammation-insulin resistance relationship 
showed that when M1 activated macrophages were knocked out, inflammatory cytokine 
expressions in muscle dropped and insulin sensitivity was regained [156]; and when an 
anti-inflammatory protein is knocked out in macrophages, muscle inflammation and 
insulin resistance increased [171]. Skeletal muscles of HFD-fed mice were shown to 
contain CD11c+ macrophages and when the macrophages are depleted insulin resistance 
and inflammation seems to be prevented [155, 156]. Our own lab has shown in several 
studies that HFD-fed mice displayed increased levels of CD68, F4/80 macrophage markers, 
and TNFα, IL-6, C-C motif chemokine ligand 2 (Ccl2) cytokines in skeletal muscle [93, 
133, 172].  
Some researchers believe that the source of inflammation in muscle is 
intramyocellular adipose depot and adipocytes recruit macrophages [78, 155, 157, 173]. 
However, a recent study by our lab showed exercise-mediated weight loss improved insulin 
sensitivity in obese mice without affecting adipose tissue inflammation, but by reducing 
local inflammation in muscle. This finding supported the role that muscle inflammation is 
playing in obesity-induced insulin resistance [133]. Elevated fatty acids in circulation 
during obesity can be considered as another factor that induces inflammation in skeletal 
muscle through NF-κB [146, 174]. When muscle cells are co-cultured with macrophages, 
fatty acid treatment caused inflammatory cytokine TNFα, IL-6 release, JNK/IKKβ 
activation, and insulin resistance in muscle cells directly, which suggests adipokines are 
not necessary to start inflammation and insulin resistance in muscle [141, 168].   
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Anti-inflammatory agents like aspirin were shown to attenuate muscle insulin 
resistance in obese rats by inhibiting NOS production, IKKβ/JNK activation and restoring 
Akt signaling, which shows the importance of inflammation in muscle insulin resistance 
[175]. This study also shows the direct effect of aspirin on cultured muscle cells suggesting 
that it is targeting directly muscle, not the adipose tissue. Other anti-inflammatory agents 
like anti-TNFα antibody also result in improved insulin signaling in muscle [176]. 
Endoplasmic reticulum (ER) stress also recently became prominent in the obesity-
inflammation research field [177]. ER stress in obese pregnant women, mouse, and 
myocyte cultures was also found to contribute to skeletal muscle inflammation and insulin 
resistance [178, 179]. 
All these findings support the important role of obesity-induced skeletal muscle 
inflammation in the pathogenesis of type 2 diabetes, and further investigation is clearly 
needed to clarify the mechanisms associating obesity-muscle inflammation-insulin 
resistance for reaching an in-depth understanding of the metabolic syndrome.   
1.2.4 Skeletal Muscle in Obesity and Aging 
Aging results in decline in skeletal muscle mass termed ‘sarcopenia’ since 1989 
[180] as a combination of the words ‘sarco’ (flesh) and penae (deficiency) in Greek. It is 
described as ‘muscle mass below two standard deviations of a young control group’ [181]. 
Muscle mass and function decrease yearly 2% up to 40-50% after the 50’s [182-185]. This 
decrease poses a threat to healthy aging. 
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Sarcopenia is associated with type 2 diabetes and they both display an increased 
inflammatory phenotype [186, 187]. Inflammation in skeletal muscle during aging is 
shown to cause degenerated muscle fibers and proteins [188-190]. Pro-inflammatory 
cytokines are found to be higher in skeletal muscles of the elderly, and in return, they 
contribute to sarcopenia [128-131]. As an example, researchers found that skeletal muscles 
in elderly contained higher IL-1β levels compared to young subjects, and macrophage 
response due to physical activity in aging muscles was impaired [191]. Increased levels of 
circulating IL-6 and TNFα and decreased levels of circulating IL-10 concentrations were 
again correlated with lower muscle mass and strength in healthy elderly [84, 192-194]. 
Apart from inflammation, skeletal muscle protein synthesis is also resistant to the anabolic 
action of insulin in older subjects resulting in muscle loss in the old population [195]. 
In elderly, sarcopenia and obesity can progress synergistically making the condition 
even worse and leading to insulin resistance [49, 196]. Obesity is another factor that can 
impair the muscle mass balance. With increasing overload, anti-gravity muscles of obese 
people initially grow larger for a while [197], but the muscle performance does not 
improve. Muscle regeneration is another factor impacted by obesity. Satellite cells were 
shown to be impaired with increasing lipid accumulation at later stages of obesity [198, 
199]. Skeletal muscle wasting during high-fat feeding might be related to impaired satellite 
cell function, since the wasting could be reversed by mesenchymal stem cell administration 
[200]. Moreover, infiltrated intramyocellular fat in skeletal muscle during obesity can 
cause loss of muscle function and strength in people [201]. Aging muscle also faces a 
decrease in satellite cell number, regeneration, and activity [202]. Taken together, during 
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both aging and obesity muscle growth, repair, strength, and function are impaired, 
decreasing the life quality of old and overweight people. 
1.3 Inflammation 
1.3.1 HFD-related Impairment of Immune Function 
The detrimental effects of HFD on the immune system were known as early as 
1980’s. T cell, B cell responses, macrophage and natural killer (NK) cell activities were all 
altered in HFD-fed animals [203]. Studies report that HFD results in a decrease in 
lymphocyte proliferation, and an increase in phagocytic activities is causing a more pro-
inflammatory response type [204]. Adipose tissue-resident macrophages are suggested to 
be the main source of inflammation in type 2 diabetes and obesity [205]. Researchers found 
that HFD increases CD11c+ CD11b+ subset of dendritic cells in the adipose tissue resulting 
in M1 polarization in macrophages [155, 206]. Macrophages are not the only immune cell 
types that are triggered in HFD-induced inflammatory response. T lymphocyte activation 
even precedes the macrophages in HFD-fed mice increasing the macrophage activation and 
recruitment [207]. Our lab has shown that genetic ablation of lymphocytes protects against 
diet-induced obesity in mice [208]. B cells also accumulate in adipose tissue in HFD-fed 
mice, increasing inflammatory immunoglobulin and cytokine concentrations and 
polarizing macrophages and lymphocytes to induce insulin resistance [209]. Taken 
together, these findings imply that HFD-feeding is causing changes in multiple components 
of the immune system altering its working balance completely. 
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1.3.2 Aging-related Impairment of Immune Function  
Inflammatory markers increase with age creating a pro-inflammatory state [186, 
210, 211], popularly referred to as ‘inflamm-aging’ nowadays [212-215]. This constant 
inflammatory state is associated with multiple metabolic disorders and makes it hard to 
maintain a healthy lifespan in elderly. Like obesity-mediated inflammation, aging-
associated inflammation is a persistent low-grade inflammation unlike the canonical 
inflammatory response. It might be caused by accumulated cell debris due to insufficient 
recycling and toxic mediators released from them, pathogenic organism debris resulting 
from impaired immune system during aging, increased cell senescence or 
immunosenescence of the immune system [212]. ROS in circulation is another factor going 
up during aging that can contribute to inflammation [216]. As some components of the 
immune response diminish with age, other components start to show a subtle hyper-
activation disturbing the balance. As the traditional response to pathogens worsens, 
unnecessary chronic activation of inflammatory agents takes place. 
Aging-related changes in immune cells is called ‘immunosenescence’ [217]. Aging 
can result in thymic atrophy that impairs T cell function, and while memory T cells are 
increasing with age, naïve T cells diminish, changing the T cell environment [218, 219]. 
Organ-specific B cell proliferation and diversity can also decrease with age [220]. 
Macrophages, on the other hand, are constantly activated which results in a constant pro-
inflammatory state. These imbalances in the immune cell repertoire prevent the immune 
system from responding appropriately to stimuli. 
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Inflammaging is shown to be associated with increased instances of diabetes, 
cardiovascular disease, obesity and neurological disorders in elderly. Aging increases 
expression of inflammatory mediators in the cardiovascular system that may be linked to 
atherosclerosis [221]. Elevated circulating levels of IL-6 and [222] and TNFα [223] 
detected in elderly were found to be associated with mortality, and even used as risk 
markers in elderly [224, 225]. The exaggerated inflammatory response in aging also may 
be caused by declining anti-inflammatory IL-10 levels with age [226]. Even though a 
significant amount of studies focuses on inflammaging, the complete picture is not revealed 
yet. As more detailed studies are conducted on aging-induced inflammation, preventive 
methods can be developed to increase healthspan in late life. 
1.3.3 Anti-inflammatory Approach for Diabetes and Insulin Resistance 
Since chronic low-grade inflammation is correlated with serious health risks 
including diabetes, obesity, sarcopenia and cardiovascular disease [215], strategies to 
prevent this basal inflammation gain importance. Therapeutic interventions targeting 
inflammation are therefore being investigated to improve life quality in diabetic patients.  
Salicylates, commonly used painkillers that block IKKβ pathway, were shown to 
prevent insulin resistance in lipid-induced, type 1 diabetic and obese rodents [33, 227, 228]. 
Salsalate (a prodrug dimer of salicylates) was in clinical trials for cardiovascular diseases 
and diabetes. The initial results of clinical studies for salsalate showed variance according 
to the patient characteristics. However, 7 independent clinical trials have shown some 
improvement of glycemia with salsalate [229-235]. One clinical trial suggested salsalate 
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consistently showed clinical efficacy in the treatment of type 2 diabetes in different patient 
groups [233]. Likewise, in another study salsalate-treated type 2 diabetic patients had lower 
insulin, c-peptide and glycemia levels [236]. A more recent clinical trial that assessed the 
long-term efficacy and safety of salsalate in patients who were being treated for type 2 
diabetes showed that salsalate improved glycemia and decreased inflammation in type 2 
diabetic patients [232]. However, body weight, low density lipoprotein cholesterol levels 
and urinary albumin levels were higher in the salsalate-trated group, suggesting possible 
adverse effects of salsalates in cardiovascular and renal metabolism. Also, a limitation of 
this study was ~300 patients were tested during one year, so a longer-duration trial was 
suggested as a next step. The effect of salsalates on cardiovascular disease is currently 
being investigated in clinical trials and has not been concluded yet (*Clinicaltrials.gov; 
Trial #NCT00624923 Targeting Inflammation Using Salsalate in CardioVascular Disease 
(TINSAL-CVD)). More studies are required to investigate the renal and cardiovascular 
effects of long-term salsalate treatment. 
In obese patients, salsalate did not reduce coronary plaque formation during a recent 
clinical trial [237]. However, it reduced total white blood cell, lymphocyte, monocyte, and 
neutrophil counts and increased adiponectin levels without changing C-reactive protein 
levels. Moreover, fasting glucose and triglycerides levels in this study were lower in the 
salsalate treatment group compared with the controls suggesting a positive role for salsalate 
in metabolism [237]. 
In clinical trials with prediabetic patients, the results were less promising. Salsalate 
was reported to reduce fasting plasma glucose and HbA1c levels in the trials [230, 231, 
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235]. However, while the first study suggested that salsalate treatment reduced insulin 
resistance [235], subsequent studies did not report any increase in peripheral insulin 
sensitivity and suggested additional mechanisms for metabolic improvement [230]. An 
intriguing finding in the prediabetic and non-diabetic obese patient trials was that salsalate 
reduced insulin clearance, which may be beneficial for diabetes treatment [230, 238, 239].  
Circulating inflammatory cytokines are elevated in obesity, insulin resistance, and 
sarcopenia. TNFα antagonists like ‘etanercept’ and ‘infliximab’ that are used commonly 
for the treatment of rheumatoid arthritis and inflammatory bowel disease were shown to 
have preventive effects on insulin resistance and sarcopenia [240-244]. However, other 
studies did not report a significant improvement in glucose levels of type 2 diabetic patients 
treated with TNFα antagonists [245-248]. Anakinra, the antagonist for the major pro-
inflammatory cytokine IL-1β, was also shown to improve euglycemia and β cell function, 
and decrease inflammation in type 2 diabetic patients [249-252]. This effect was not 
observed in nondiabetic obese subjects [253]. Another anti-inflammatory approach is to 
use natural endogenous anti-inflammatory cytokines. Studies in our lab previously showed 
that the major anti-inflammatory cytokine IL-10 prevented IL-6-mediated inflammation 
and insulin resistance in mice [172]. Additional studies by our lab found that IL-10 infusion 
and transgenic IL-10 expression in muscle improves insulin sensitivity in short-term HFD-
fed mice [93]. However, the clinical trials of recombinant IL-10 on diabetes are halted for 
now (see below for a more detailed review of IL-10 treatment).  
Although numerous clinical trials have shown that IL-1 antagonists and salsalate 
enhance glucose metabolism [254], the findings of clinical trials for anti-inflammatory 
 
 
23 
 
mediators are not completely conclusive up to now and a better understanding of the 
inflammatory basis for diabetes and further investigation are needed to develop anti-
inflammatory therapies for inflammation-related pathologies.  
1.4 Interleukin-10 
1.4.1 Interleukin-10 Function and Signaling 
IL-10 is a 40kD homodimer Th2 cytokine previously named as ‘cytokine synthesis 
inhibitory factor’ when it was first defined [255]. It is positioned on chromosome 1 at 1q31-
32 and is very polymorphic [256]. Multiple single nucleotide polymorphism are found in 
the IL-10 5’ flanking region, and they form haplotypes that are associated with different 
IL-10 production levels.  The IL-10 gene contains the code for a 178 amino acid length 
polypeptide [257]. IL-10 production is genetically controlled by IL-10 promoter, which is 
also highly polymorphic [256]. IL-10 is the most broadly characterized anti-inflammatory 
cytokine to date. As we can understand from the previous name, it acts to suppress pro-
inflammatory response by blocking the synthesis and release of inflammatory cytokines 
and macrophage recruitment [226]. 
IL-10 is synthesized by several cell types including helper T (Th) cells, B cells and 
macrophages [226]. While in acute inflammation the main source is macrophages, in 
chronic inflammatory phenotypes IL-10 is also secreted from T cells [258]. It is a 
pleiotropic cytokine that is shown to inhibit the production of pro-inflammatory cytokines 
IL-1, IL-6, interferon (IFN)-γ, granulocyte-colony stimulating factor (G-CSF) and TNFα 
by monocytes [259, 260]. It also increases the release of anti-inflammatory soluble 
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antibodies for these cytokines [261, 262], suppresses major histocompatibility complex II 
(MHCII) expression [259], selectively inhibits transcription of inflammatory genes [263] 
and acts to suppress the expression of the chemokines that recruit macrophages [264]. Mice 
that are overexpressing IL-10 in their macrophages were shown to synthesize less pro-
inflammatory cytokines [265]. Vice versa, when IL-10 is decreased inflammatory cytokine 
release increases [266]. IL-10 has an essential function in maintaining a healthy balance 
between pro- and anti-inflammatory responses. Deletion of IL-10 can result in colorectal 
cancer [267], inflammatory bowel disease [268], osteopenia [269], motor deficits [270], 
vessel stiffness, increased heart size and impaired heart function [271]. IL-10 
overexpression was shown to suppress atherosclerosis in vivo [272]. Moreover, IL-10 
promoter polymorphisms are linked to type 1 diabetes onset age [273]. 
IL-10 relays its signal through the IL-10 receptor. In most of the cells bearing IL-
10 receptor, IL-10 induces both signal transducer and activator of transcription (STAT)1 
and STAT3, but STAT3 is the major player [258, 265, 274, 275]. Our lab showed that IL-
10 induces STAT3 phosphorylation also in skeletal muscle [93].  IL-10 binds to IL-10 
receptor activating Jak proteins by trans-phosphorylation, and they in return, phosphorylate 
IL-10 receptor generating a docking site for STAT3 [274] (Fig. 1.2). STAT3 gets 
phosphorylated at the receptor, and then translocates to the nucleus to induce STAT3 
regulated genes like suppressor of cytokine signaling (SOCS)3; which in return block 
activation of inflammatory genes [258]. IL-10 itself is immune to blocking by SOCS3 
because it lacks SOCS3 recruitment motifs in IL-10 receptor. However, SOCS3 can block 
inflammatory cytokines like IL-6 and TNFα [276]. SOCS3 can also inhibit JNK 
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phosphorylation by binding to TNF-receptor associated factor 6 [277]. Moreover, STAT3 
controls IL-10 promoter resulting in a positive feedback mechanism for increased IL-10 
expression [278]. IL-10 can block NF-κB activity through suppression of IKK and DNA 
binding capability of NF-κB, or activation of STAT3 [279, 280].  
Along with its suppressive roles, IL-10 also has the ability to convert M1 
macrophages to M2 phenotype [281].  IL-10 was shown to polarize the adipose tissue 
macrophages recruited during obesity and skeletal muscle macrophages in dystrophic mice 
towards the M2 phenotype [206, 282]. M2 polarization of macrophages by Th2 cytokines 
in obesity is important because it was shown to boost insulin sensitivity [283]. It is 
important that IL-10 can signal directly on skeletal muscle. Although the main source for 
IL-10 production is immune cells, IL-10 expression was detected in mouse and human 
skeletal muscles [93, 191, 284] and myoblast cultures [285]. Detecting IL-10 in sole 
myoblast cultures suggests that muscle fibers are able to secrete IL-10 themselves. This 
finding is also supported by IL-10 release into circulation after exercise [286-288]. 
 Our lab and others also showed that myoblasts express IL-10 receptor [93, 289], 
which suggests that IL-10 can actively signal through the skeletal muscle. The absence of 
IL-10 in the IL-10 knock out mice exacerbates response to inflammatory stimuli in the 
skeletal muscle [290]. Another finding suggesting the direct effect of IL-10 on skeletal 
muscle cells is when myoblasts are pretreated with IL-10 they can resist JNK 
phosphorylation induced by TNFα [289]. Moreover, IL-10 treatment on myoblasts can 
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Figure 1.2 IL-10 signaling 
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prevent TNFα-induced IL-6 expression and inflammatory effects of TNFα and IL-1β. 
Moreover, when IL-10 is knocked out IL-6 response upon inflammatory stimuli is elevated 
[277, 289, 291].  
Overall, these data support the notion that IL-10 is an essential cytokine in 
controlling the immune response triggered by obesity in skeletal muscle and other tissues.  
1.4.2 Interleukin-10 Receptor  
The IL-10 receptor is a transmembrane glycoprotein of class II cytokine receptor 
family [292] with a docking site for STAT3 downstream signaling [293]. The IL-10 
receptor has two chains: IL-10R1 required for STAT3 docking and IL-10R2 for class II 
cytokine signaling [294]. IL-10R1 has two tyrosine residues that when phosphorylated by 
Jak1 become docking sites for STAT3 [258]. IL-10R2 is an accessory part to bring tyrosine 
kinase 2 to the receptor complex to catalyze the trans-phosphorylation of IL-10R for 
mediation of IL-10 signaling [295]. 
IL-10R1, although expressed primarily in monocytes, is expressed in various tissue 
types including skeletal muscle, bone marrow, thymus, spleen, salivary gland, colon, liver, 
pancreas and lung [296]. The IL-10 receptor is detectable in myoblasts and muscles as 
shown by our lab and others [93, 282, 289]. Deficiency of IL-10 receptor causes severe 
defects in regulatory T cell and macrophage function and generation [297, 298]. Also, loss 
of IL-10 signaling due to IL-10 receptor ablation inhibits IL-10 release from intestine and 
bone marrow-derived macrophages, suggesting IL-10 needs to be stimulated by itself to 
increase its production [297].  
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1.4.3 Interleukin-10’s Use as a Therapeutic Approach 
IL-10 was tested as a possible therapeutic agent in autoimmune diseases due to its 
anti-inflammatory properties. The current literature in the field involves mostly negative 
results as well as a few positive results. Even though the results in rodent models look 
promising, human application of recombinant IL-10 was not effective in most cases. 
Animal models: Some studies conducted in rodent models suggest a positive effect 
of IL-10 in obesity and diabetes, depending on the method of delivery. Intramuscular 
injection of IL-10 containing plasmid to non-obese diabetic (NOD) mouse model reduced 
the incidence of diabetes [299]. Also, daily administration of human IL-10 reduced the 
severity of insulitis and promoted normal insulin production by β cells in NOD mice [300]. 
Likewise, our lab showed IL-10 co-treatment reduced the IL-6 and lipid-induced skeletal 
muscle and hepatic insulin resistance in mice [172]. However, the positive effects of IL-10 
in diabetes have not been tested in humans and its disadvantages would possibly outweigh 
the benefits.  
Very recently, Toita and colleagues synthesized and used IL-10-containing 
phosphatidylserine-liposomes that generate ‘eat me’ signals for macrophages to prevent 
the effects of obesity-induced chronic inflammation in mice [301].  This delivery method 
worked efficiently resulting in decreased cholesterol levels, inflammatory cytokine 
secretion from adipocytes, adipocyte size, and liver injury in mice. Another group tried to 
increase IL-10 levels by hydrodynamic gene delivery in mice resulting in rapid hepatic 
expression and increased levels in the circulation [302]. Oral gene delivery was also 
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successful for inflammatory bowel disease in mice [303]. Even though site-specific 
delivery of IL-10 is being studied widely in animal models, it is a big challenge to adapt it 
to humans without gene therapy. Application of recombinant IL-10 as a targeted 
therapeutic agent does not seem promising at the moment and still needs further 
improvements for managing site-specific delivery. 
Human Clinical Trials: Recombinant IL-10 termed as ‘ilodecakin’ was produced 
by drug companies (mainly Schering-Plough, NJ, USA; Tenovil®) to be tested for 
autoimmune diseases. In the last 25 years in some diseases, recombinant IL-10 showed 
mildly improved results, whereas in others such as Crohn’s disease it was ineffective and 
had possible side effects [304-308]. Most current clinical data arise from trials in Crohn’s 
disease and psoriasis patients. In Crohn’s disease, the clinical trials did not reach 
significance [309, 310], even though clinical and endoscopic improvement was observed 
in some patients [304]. Researchers suggested the level of improvement may vary due to 
IL-10 levels of the patient himself or disease stage of the patient [305, 311]. When it is 
used at low doses it was usually well-tolerated [306, 312]. However, when used at high 
doses it showed serious side effects [308, 313]. In psoriasis, only temporary effectiveness 
was reported in some  phase II trials [314], even though others suggested it decreased the 
relapse effectively [315]. Recombinant IL-10 human clinical trials to treat acute 
pancreatitis also failed and they were terminated last year. Renal transplant patients could 
tolerate low doses of IL-10, whereas high doses caused sensitization to immunosuppressant 
drugs [316]. No clinical improvement was observed in rheumatoid arthritis patients [317]. 
However, PEGylated IL-10 has been shown to induce the expansion of tumor-reactive T 
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cells and is currently being tested for anti-tumor activity in several phase I cancer trials 
[318]. 
Targeting persistent IL-10 expression to the desired tissue is an important challenge 
since the half-life of IL-10 is relatively short (~2 hours) [319] and it is an anti-inflammatory 
substance and a growth factor which could have potentially dangerous side-effects during 
long-term delivery. 
1.4.4 IL-10 Expression in Obesity and Old Age 
IL-10 is produced by many cell types and its expression during different metabolic 
states like obesity or aging is altered [226]. Hyperinsulinemia during obesity was shown to 
suppress IL-10 production by regulatory T cells [320]. Also, IL-10 levels measured from 
serum are inversely correlated with body weight, glucose intolerance and type 2 diabetes 
during hyperinsulinemic-euglycemic clamps [321]. In a study, IL-10 levels were shown to 
be elevated in obese women, yet low IL-10 levels in circulation were found to be associated 
with metabolic syndrome in this population [322]. However, in another study IL-10 
promoter polymorphisms were linked to obesity and insulin resistance [323]. IL-10 levels 
are not only altered in circulation during obesity. Previous studies by our lab found that 
muscle IL-10 levels are decreased as well in HFD-fed and obese mouse models [93]. Even 
though there are a few studies suggesting otherwise, IL-10 levels were also decreased in 
adolescent obesity models. Studies performed on young adolescents showed decreased 
circulating IL-10 levels associated with obesity [324]. IL-10 was also found to have 
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receptors in the hypothalamus and prevent hyperphagia-related obesity due to increased 
insulin and leptin sensitivity in the hypothalamus [325].  
IL-10 levels are altered during aging as well. There is contradicting data describing 
both elevated and decreased expression of IL-10 during senescence. Nevertheless, the 
majority of the studies support declining IL-10 levels with age. IL-10 expression was found 
to be decreased in muscles of elderly after exercise compared to young subjects [191]. 
Although IL-10 levels were decreased in elderly, certain genotypes associated with high 
IL-10 production were found to be related to longevity and successful aging in men [326]. 
Researchers have found that low IL-10 production capacity was correlated with high 
plasma glucose, high HbA1c, type 2 diabetes, and dyslipidemia. Also, the high production 
capacity of IL-10 was associated with muscle strength in aging people [194]. This effect 
was observed in both genders, since high IL-10 and low IL-6 levels due to single nucleotide 
polymorphisms in aging females were also associated with improved physical performance 
[327]. This was also true for animal models. Aging IL-10 knock out (KO) mice were shown 
to develop inflammatory pathway activation and have decreased muscle strength [328]. 
Moreover, the longer average lifespan of Dark Agouti rats was attributed to their ability to 
retain macrophage IL-10 production during aging [329]. IL-10 levels are not just decreased 
in circulation in elderly. Intracellular organ-specific content of IL-10 were also shown to 
be lower in skeletal muscles of aging mice [330]. In this study researchers measured IL-10 
and IL-6 content in aging and young mice organ lysates (addressing the intracellular 
compartment) and organ-conditioned media. They found that intracellular organ 
expression of IL-10 in old vs young mice was lower as detected by ELISA and 
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immunohistochemistry. However, organ-conditioned media IL-10 levels were higher in the 
aging group. Lowered IL-10 levels in old age was also found to be associated with the 
insulin resistance. Leiden 85-Plus study that was performed with 599 elderly subjects has 
revealed that IL-10 production capacity is linked to metabolic syndrome and type 2 
diabetes [331]. IL-10 decrease with age can also generate an elevated inflammatory 
phenotype. IL-6 expressions were highly elevated in skeletal muscles of old but not young 
IL-10 knock out mice in response to inflammatory stimuli [290]. 
Overall, the current literature mostly defines a decrease in IL-10 expression in 
obese and aging subjects which may result in an increased pro-inflammatory state; and 
polymorphisms that are linked to the higher expression of IL-10 are associated with a 
general healthier metabolic state.  
1.4.5 Role of IL-10 in Whole Body and Muscle Glucose Metabolism 
Since obesity-mediated insulin resistance is associated with chronic inflammation, 
the major anti-inflammatory cytokine IL-10 was a potential target in metabolism research 
for our lab and others. The Leiden study carried out in large populations revealed that low 
production capacity of IL-10 was associated with increased type 2 diabetes and metabolic 
syndrome occurrence [331]. Our lab was the first to show that IL-10 co-treatment prevents 
IL-6 and lipid-mediated insulin resistance in mice, especially in the skeletal muscle [172]. 
A 3-day IL-10 infusion also improved whole-body, hepatic and muscle insulin sensitivity 
[93]. Since our observation for insulin-sensitizing effect of IL-10 was mainly in muscle, 
our lab generated a transgenic mouse model that overexpresses IL-10 selectively in skeletal 
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muscle [93].  Short term HFD-fed ‘MIL10’ mice were protected from whole-body and 
skeletal muscle insulin resistance, and skeletal muscle inflammation. These experiments 
defined IL-10 as a potential anti-inflammatory agent to prevent inflammation-mediated 
insulin resistance in muscle. 
Other labs have also shown that when LPS triggers a pro-inflammatory response in 
macrophages IL-10 is elevated, and muscle cells become more insulin sensitive. However, 
when fatty acids trigger pro-inflammatory response in macrophages inflammatory 
cytokines are released instead which impair insulin signaling in skeletal muscle [141]. In 
this study, IL-10 treatment of muscle cells improved insulin action and GLUT4 
translocation in skeletal muscle fibers and decreased the actions of MCP-1 to impair 
insulin-stimulated glucose uptake in skeletal muscle [164].  
The positive effects of IL-10 are not limited to muscle insulin resistance. IL-10 was 
also shown to ameliorate endothelial dysfunction during type 2 diabetes [332]. 
Furthermore, intermuscular injection of IL-10-containing vector ameliorated insulitis in 
type I diabetic mice [299]. In another study, intramuscular IL-10 coding-adeno-associated 
virus injection raised serum IL-10 levels 12-fold in obese Zucker rats and ameliorated renal 
function and insulin sensitivity [333]. 
A recent study showed that hydrodynamic i.v. delivery of IL-10 gene to HFD-mice 
prevented weight gain, insulin resistance, adipose tissue inflammation and ectopic fat 
accumulation in the liver [302]. The biggest limitation of this study according to us was 
although the whole-body insulin sensitivity was largely improved, the researchers did not 
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look at any parameters in skeletal muscle. In another study that has been very recently 
published, researchers injected an adeno-associated virus that is expressing IL-10 into 
ob/ob mice and raised plasma IL-10 levels 60-fold [334]. This resulted in decreased 
hyperphagia, obesity, insulin resistance and adipose tissue inflammation in ob/ob mice. 
The scientists proposed hypothalamus and white adipose tissue (WAT) as target tissues for 
IL-10 where STAT3 phosphorylation was increased. However, interestingly the 
researchers did not look at the effects in skeletal muscle where they injected the virus.  
All these studies define IL-10 as a possible mediator in metabolism research and 
suggest further studies should follow [299-302, 325, 334]. 
1.5 IL-10 and Myogenesis 
Interestingly IL-10’s positive effects on muscle are not confined to glucose 
metabolism. We have serendipitously discovered constructive effects of IL-10 on muscle 
mass during our studies. IL-10’s ability to prevent pro-inflammatory cytokine release is 
promising for preventing inflammation-mediated muscle loss. Several other studies that 
have been published recently also defined a constructive role for IL-10 in skeletal muscle 
growth. As an example, when the intestines of the IL-10 whole-body knock out mice 
(model for inflammatory bowel disease) were inoculated with a mixture of bacteria the 
mice showed decreased skeletal muscle growth and growth-related proteins and ribosome 
biogenesis [335]. In another study, IL-10 ablation in dystrophic mice decreased muscle 
structure and function; and IL-10 re-treatment reduced M1 activation, polarized muscle 
macrophages to M2 phenotype and increased muscle regeneration in dystrophic mice 
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[282]. IL-10 was also shown to reduce myoblast necrosis in newborn rodents that had 
hypoxia-induced skeletal muscle injury [336]. 
One of the reasons that IL-10 can prevent muscle loss is, its abilities to suppress 
pro-inflammatory cytokines. Pro-inflammatory cytokines that are released during obesity-
induced low-grade chronic inflammation such as TNFα and IL-6 can interfere with skeletal 
muscle growth. For example, it is shown that IL-6 infusion into skeletal muscles lowered 
muscle protein content and blocked muscle growth signaling and insulin’s anabolic effects 
[337]. TNFα, IL-1β, and IL-6 can be secreted by skeletal muscle cells as well as immune 
cells upon inflammatory stimuli, and they can decrease insulin-like growth factor-I (IGF-
I) content in skeletal muscle [150, 338-340]. Also as a feedback loop, TNFα and IL-1 can 
increase IL-6 expression in myoblasts [152]. TNFα as an inflammatory cytokine was 
shown to block muscle protein synthesis, decrease protein content and myogenin 
expression which is essential for muscle differentiation [341-343]. Another inflammatory 
cytokine IL-1β was found to activate NF-κB, and the major muscle atrophy proteins muscle 
ring-finger protein 1 (MURF1) and muscle atrophy f-box (MAFbx) in mouse myoblasts 
[344, 345]. Expression of IGF-I in skeletal muscle, which is also an essential mediator of 
skeletal muscle growth, is also decreased with TNFα and IL-1β [338, 340, 346]. Research 
on myoblasts shows that IL-10 can completely suppress TNFα’s JNK-mediated negative 
effects to inhibit myogenin-induced myogenesis [289].  Inflammatory cytokines can also 
impair muscle growth by decreasing Akt activation. Akt activation is essential for muscle 
growth, and even acute conditional Akt activation in mice can induce rapid hypertrophy in 
skeletal muscles [347]. IGF-I also stimulates the muscle growth due to muscle load through 
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PI3K-Akt pathway [348, 349]. Akt/mTOR (mammalian target of rapamycin) signaling is 
especially important for muscles that undergo compensatory hypertrophy due to weight-
bearing, as in the case of obesity [350].  
Muscle wasting is associated with insulin resistant and insulin-deficient conditions 
and was observed in diabetic rodents [351, 352]. Insulin itself is a growth hormone [353]. 
Therefore, IL-10 by its insulin sensitizing effect may also exert a positive effect on muscle 
mass maintenance. IL-10 itself is also a potent growth factor for B lymphocytes [260], and 
skeletal muscle has receptors for IL-10 [93]. So, it is possible that it may act as a growth 
factor on muscles. More interestingly, IL-10 was found to have insulin-like effects in 
adipose cells that may explain IL-10 associated growth. It is observed that IL-10 treated 
adipocytes have increased IRS-I and PI3K signaling and show immediate phosphorylation 
of Akt [206, 354]. 
Although other researchers have not found a direct proliferative effect of IL-10 on 
myoblast cultures like we did; they have demonstrated that IL-10 treated myocyte-
macrophage co-cultures show increased proliferation [355]. After muscle atrophy, IL-10 
depletion impaired M1 to M2 conversion and decreased muscle growth [355].  M1 
polarization can have adverse effects on muscle growth. Hence when myotubes are 
cultured with M1 polarized macrophages, the expression of atrophy genes like MAFbx or 
MURF1 were shown to increase [168]. Also, IL-10 was shown to restore IGF-I induced 
muscle growth that is suppressed by inflammation [277]. Specifically, researchers 
demonstrated that IGF-I induced-myogenin expression was inhibited by TNFα and IL-1β, 
and IL-10 could prevent this by intervening TNFα- and IL-1β-induced JNK 
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phosphorylation [277, 289]. In those studies, IL-10 was found to enhance differentiation 
and protect myoblasts when IGF-I and TNFα are present [289]. 
In the light of all these data, we can conclude that IL-10 has potential to prevent 
muscle wasting during insulin resistant conditions. Since we observed IL-10’s positive 
effect on multiple insulin resistant states it stands as a promising target. Therefore, more 
detailed studies should be conducted to define the mechanism of this effect. 
1.6 Mouse Models  
1.6.1 Long-term HFD-fed MIL10 Mice 
MIL10 mice: MIL10 mouse was designed to generate a model that elevates IL-10 specifically 
in skeletal muscles within a physiological range [93]. In C57/BL6J mice IL-10 gene was 
placed under a 1.3 kb segment of a modified muscle creatine kinase promoter. Transgene 
expression was restricted to skeletal muscle to avoid any potential consequences of 
expression in cardiac muscle by using a promoter in which 3 E-boxes responsible for 
cardiac expression are mutated [93, 356, 357]. An untranscribed sequence of human growth 
hormone was also added after IL-10 sequence to increase transcription efficiency and make 
genotyping easier. IL-10 levels in skeletal muscle were only elevated 2-fold under chow 
and HFD to stay at a physiological level and avoid cytotoxicity. IL-10 levels were not 
increased in other metabolic organs such as liver, WAT or heart under chow diet [93]. Also 
under chow-fed conditions, MIL10 mice were similar to wild-type counterparts in terms of 
body weight, body composition, muscle structure, metabolic activity and physical 
appearance [93]. MIL10 mice fed with 3-week short-term diet were less hyperglycemic, less 
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hyperinsulinemic and more insulin sensitive than wild-type mice especially in the skeletal 
muscle [93]. This was due to the decreased macrophage numbers and pro-inflammatory 
cytokine levels in the skeletal muscles of short-term HFD-fed MIL10 mice.  
1.6.2 MCK-IL10ob/ob Mice 
Leptin-deficient ob/ob model: Obesity is not just triggered in response to high-fat 
nutrition content. Obesity can also develop due to genetic mutations in the genes 
responsible for satiety mechanism. Adipocytes secrete a 16 kD weight hormone called 
leptin which is essential for transmitting a satiety signal to the hypothalamus [358]. It is 
synthesized by the ob gene where single point mutations result in morbid obesity when 
homozygous. This mutation was spontaneously discovered in Jackson Labs back in the 
1950’s where they observed mice that were weighing as twice of their littermates [359]. 
Mice that have the homozygous mutation for ob gene are hyperphagic, hyperglycemic and 
hyperinsulinemic [360]. They fit in a model similar to type 2 diabetes symptoms, therefore 
are suitable models for studying genetic obesity-induced insulin resistance. Leptin is 
known to have a role in regulating immune response, since most immune cells express 
leptin receptors. It can protect against T cell and macrophage proliferation and death [361]. 
To study the effects of IL-10 in a non-high-fat diet-mediated obesity model we crossed 
MIL10 mice with ob/+ mice (both on C57BL/6J background) to generate muscle creatine 
kinase (MCK)-IL10ob/ob mice. The mice were back-crossed for several generations to 
obtain genotypically heterogeneous MCK-IL10ob/ob mice that lack leptin and overexpress 
IL-10 specifically in skeletal muscle. 
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1.6.3 Aging MIL10 Mice 
Aging itself was shown to be associated with insulin resistance in human and mouse 
models [44, 362]. MIL10 mice were generated on C57/BL6J background, and C57/Bl6 mice 
enter aging period by 18 months [363]. Therefore, for our aging model we maintained MIL10 
mice until they reach 18 months on standard chow diet. MIL10 mice and WT siblings were 
then used in our metabolic experiments. 
1.6.4 HFD-fed IL10R KO Mice 
MCK-Cre IL10R1 KO model: Both IL-10 receptor 1 (R1) and 2 (R2) are 
necessary for IL-10 signaling [364, 365]. Binding of dimeric IL-10 crosslinks R1 and R2 
chains and relays the signal [260]. Therefore, in our mouse model lacking the main R1 
chain, no IL-10 signal is conducted in skeletal muscle fibers. To generate the muscle IL-
10 receptor knock out model we crossed muscle creatine kinase-Cre mice with IL-10 
Receptor 1 fl/fl mice kindly donated by Dr. Werner Muller from University of Manchester, 
UK. Since muscle creatine kinase was abundantly expressed in skeletal muscles, IL-10 
receptor was excised from floxed sites by Cre-lox recombination [366] 
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2.1 Abstract  
Skeletal muscle insulin resistance is a major characteristic of obesity and type 2 
diabetes. Although obesity-mediated inflammation is causally associated with insulin 
resistance, the underlying mechanism is unclear. To investigate the role of skeletal muscle 
inflammation in chronic obesity-mediated muscle insulin resistance, we examined the 
effects of chronic obesity in mice with muscle-specific overexpression of interleukin-10 
(MIL-10). After 16 weeks of a HFD, MIL-10 mice became markedly obese but showed 
improved insulin action compared to that of wild-type mice, which was largely due to 
increased glucose metabolism and reduced inflammation in skeletal muscle. Since leptin 
regulates inflammation, the beneficial effects of IL-10 were further examined in leptin-
deficient ob/ob mice. Muscle-specific overexpression of IL-10 in ob/ob mice (MCK-IL-
10ob/ob) did not affect spontaneous obesity, but MCK-IL-10ob/ob mice showed increased 
glucose turnover compared to that in ob/ob mice. Lastly, mice with muscle-specific 
ablation of IL-10 receptor (M-IL10R-/-) were generated to determine whether IL-10 
signaling in skeletal muscle is involved in IL-10 effects on glucose metabolism. After an 
HFD, M-IL10R-/- mice developed insulin resistance with reduced glucose metabolism 
compared to that in wild-type mice. Overall, these results demonstrate IL-10 effects to 
attenuate obesity-mediated inflammation and improve insulin sensitivity in skeletal 
muscle, and our findings implicate a potential therapeutic role of anti-inflammatory 
cytokines in treating insulin resistance and type 2 diabetes. 
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2.2 Introduction 
Obesity has emerged as a global problem in recent decades and is associated with 
numerous human diseases including insulin resistance, type 2 diabetes, and cardiovascular 
diseases [367, 368]. The underlying mechanism by which obesity induces numerous health 
problems remains poorly understood.  In that regard, increasing evidence suggests an 
important role of dysregulated immune system in obesity-mediated insulin resistance [30, 
369].  Obesity is characterized by altered levels of circulating cytokines, and adipose tissue 
macrophage and inflammation have been causally associated with insulin resistance [78, 
370].  However, recent studies have challenged this earlier notion on the causal role of 
adipose tissue macrophages and inflammation in the development of insulin resistance 
[133, 371]. 
While adipose tissue is widely viewed as the epicenter of obesity-mediated 
inflammation, it is not the only organ shown to develop macrophage infiltration and 
inflammation in obesity. In fact, recent studies indicate that obesity-mediated inflammation 
and macrophage accumulation develop in multiple organs, including skeletal muscle, liver, 
pancreas, heart, and brain [89, 93, 372-374]. In that regard, our recent study found that 
exercise-mediated weight loss improved insulin action without affecting adipose tissue 
inflammation in diet-induced obese mice [133]. Additionally, improved insulin action 
following weight loss was associated with reduced local inflammation in skeletal muscle, 
suggesting an important role of muscle inflammation in obesity-mediated insulin resistance 
[133]. These findings clearly contest the “adipocentric” view of insulin resistance. 
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Therefore, we aimed to investigate the relationship of muscle inflammation with insulin 
resistance. 
IL-10 is a Th2-type cytokine that inhibits the synthesis and activity of pro-
inflammatory cytokines and counteracts Toll-like receptor-mediated inflammation [375-
377]. We have previously shown that transgenic expression of IL-10 selectively in skeletal 
muscle improved glucose metabolism in mice after 3 weeks of an HFD [93]. While our 
previous data suggested a potential therapeutic role of IL-10 in type 2 diabetes, our 
interpretation was limited due to a short-term feeding of HFD not resulting in mice having 
developed type 2 diabetes phenotypes (i.e., hyperglycemia). We hypothesized that anti-
inflammatory IL-10 expression in skeletal muscle would suppress local inflammation and 
insulin resistance during chronic obesity. Therefore, the current study was designed to 
specifically examine the role of IL-10 in markedly obese and diabetic mice after 16 weeks 
of an HFD (chronic HFD), a better representation of obese type 2 diabetic subjects. 
Additionally, leptin is an important adipocyte-derived hormone that is elevated in obesity 
and regulates numerous physiological functions including energy balance and 
inflammation [361]. Thus, the present study also examined the effects of muscle-specific 
transgenic expression of IL-10 on glucose metabolism in leptin-deficient ob/ob mice. 
Lastly, we examined whether IL-10 signaling in skeletal muscle is directly responsible for 
IL-10 effects on muscle glucose metabolism using a newly generated mouse model lacking 
IL-10 receptor 1 type chain selectively in skeletal muscle. Our findings indicate that 
selective targeting of IL-10 signaling in skeletal muscle improves glucose metabolism in 
obese and diabetic mice following chronic HFD or deficient in leptin and further 
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demonstrate that these effects are mediated by direct activation of IL-10 signaling in 
skeletal muscle.   
2.3 Materials and Methods 
Chronic HFD in MIL10 mice Male transgenic mice with muscle-specific overexpression 
of IL-10 (MIL10) and wild-type (WT) littermates were fed with HFD (55% fat by calories; 
Harlan Teklad TD93075, Madison, WI, USA) or standard chow diet (Labdiet Prolab Isopro 
RMH 3000 5P75, St. Louis, MO, USA) ad libitum for 16 weeks (n=6/group). During 
chronic high-fat feeding, we performed a weekly measurement of body composition to 
determine the changes in whole-body fat and lean mass. 
Generation of MCK-IL10ob/ob mice We generated leptin-deficient mice with muscle-
specific overexpression of IL-10 (MCK-IL10ob/ob) by cross-breeding MIL10 mice with ob/+ 
heterozygous mice (purchased from the Jackson Laboratory, Bar Harbor, ME, USA). The 
F1 female MCK-IL10ob/+ mice were then intercrossed with male ob/+ mice to generate 
MCK-IL10ob/ob mice.  The metabolic studies were conducted in MCK-IL10ob/ob mice that 
have been backcrossed for more than 5 generations (ob/ob, n=7; MCK-IL10ob/ob, n=12). 
Generation of M-IL10R-/- mice Mice lacking IL-10 signaling in skeletal muscle (M-
IL10R-/-) were generated by cross-breeding MCK-Cre expressing mice (kindly donated by 
Dr. Roger J. Davis) and floxed IL10R1-/- mice (kindly donated by Werner Muller). The 
metabolic studies were conducted in M-IL10R-/- mice that have been backcrossed for 
several generations. M-IL10R-/- mice and MCK-Cre mice (referred to as WT) serving as 
controls were fed with HFD or chow diet for 6 weeks (n=6-11/group). All mice were 
housed under controlled temperature (23°C) and light/dark cycle with free access to food 
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and water.  The animal studies were approved by the Institutional Animal Care and Use 
Committee of the University of Massachusetts Medical School. 
Body composition and energy balance Whole body fat and lean mass were non-
invasively measured using 1H-magnetic resonance spectroscopy (MRS) (Echo Medical 
Systems, Houston, TX, USA). Indirect calorimetry and energy balance parameters 
including food/water intake, energy expenditure, respiratory exchange ratio, and physical 
activity were non-invasively assessed for 3 days using metabolic cages (TSE-Systems Inc., 
Bad Homburg, Germany). We used the TSE-Systems LabMaster platform with easy-to-
use calorimetry featuring fully-automated monitoring for food and water and activity in x, 
y, z planes. Labmaster cages that are most similar to facility home cages were used, thereby 
allowing the use of bedding in the cage and minimizing any animal anxiety during the 
experimental period.  The system provides intuitive software with flexibility for 
experimental setup and data utilization. 
Hyperinsulinemic-euglycemic clamp Following chow or HFD, a survival surgery was 
performed at 5~6 days before clamp experiments to establish an indwelling catheter in 
jugular vein. On the day of clamp experiment, mice were fasted overnight (~17 hrs), and a 
2-hr hyperinsulinemic-euglycemic clamp was conducted in conscious mice with a primed 
and continuous infusion of human insulin (150 mU/kg body weight priming followed by 
2.5 mU/kg/min; Humulin, Eli Lilly, IN, USA) [172]. To maintain euglycemia, 20% glucose 
was infused at variable rates during clamps. Whole body glucose turnover was assessed 
with a continuous infusion of [3-3H]glucose (PerkinElmer, Waltham, MA, USA), and 2-
deoxy-D-[1-14C]glucose (2-[14C]DG) (PerkinElmer, Waltham, MA USA) was 
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administered as a bolus (10 Ci) at 75 min after the start of clamps to measure insulin-
stimulated glucose uptake in individual organs. At the end of the clamps, mice were 
anesthetized, and tissues were taken for biochemical analysis. 
Biochemical analysis and calculation Glucose concentrations during clamps were 
analyzed using 10 l plasma by a glucose oxidase method on Analox GM9 Analyser 
(Analox Instruments Ltd., London, UK). Plasma concentrations of [3-3H]glucose, 2-
[14C]DG, and 3H2O were determined following deproteinization of plasma samples as 
previously described [172]. For the determination of tissue 2-[14C]DG-6-Phosphate 
content, tissue samples were homogenized, and the supernatants were subjected to an ion-
exchange column to separate 2-[14C]DG-6-P from 2-[14C]DG. Plasma insulin levels were 
measured using an enzyme-linked immunosorbent assay (ELISA) kit (ALPCO 
Diagnostics, Salem, NH, USA). Intramuscular triglyceride concentrations were determined 
by homogenizing muscle samples (quadriceps) in chloroform-methanol and using a 
triglyceride assay kit (Sigma, St. Louis, MO, USA). 
Rates of basal hepatic glucose production (HGP) and insulin-stimulated whole-
body glucose turnover were determined as previously described [172].  Insulin-stimulated 
rate of HGP was determined by subtracting the glucose infusion rate from whole-body 
glucose turnover.  Whole body glycolysis and glycogen plus lipid synthesis from glucose 
were calculated as previously described [172]. Insulin-stimulated glucose uptake in 
individual tissues was assessed by determining the tissue (e.g., skeletal muscle) content of 
2-[14C]DG-6-phosphate and plasma 2-[14C]DG profile. The level of plasma non-esterified 
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fatty acids is measured by NEFA kit (Zenbio, Durham, NC, USA) according to 
manufacturer’s protocol. 
Molecular analysis for insulin signaling and inflammation Skeletal muscle (quadriceps) 
and liver samples were collected at the end of clamp experiments to assess insulin signaling 
by immunoblotting with rabbit monoclonal antibodies against Akt and p-Akt-Ser473 (Cell 
signaling, Danvers, MA, USA). Muscle samples were homogenized, and plasma and 
homogenized muscle samples are used to measure levels of interleukin IL-6, IL-10, IFN-
γ, and IL-1α by Luminex 200 Multiplex ELISA platform (Millipore, Darmstadt, Germany).  
Plasma IL-10 levels were measured using an ELISA kit (Abcam, Cambridge, UK). For 
quantitative RT-PCR (qRT-PCR), RNA isolation was performed with homogenized 
muscle (gastrocnemius and quadriceps), liver and WAT samples using TRIzol (Life 
Sciences, Carslbad, CA, USA) according to manufacturer’s protocols. cDNA was 
synthesized from 2 µg of total RNA by use of Omniscript cDNA synthesis kit (Qiagen, 
Venlo, Netherlands). cDNA and SYBRgreen supermix (Bio-rad, Hercules, CA, USA) was 
run in Biorad-CFX96 real time system with the primers (Table 2.1). Relative gene 
expression was calculated compared to the expression of the housekeeping gene. 
Histologic analysis Muscle samples (gastrocnemius) were collected, fixed in 10% neutral 
formalin for 48 hours, and embedded in paraffin blocks. 5 µm sections were taken and 
stained with hematoxylin-eosin (H&E). Images were taken under 20X magnification. 
Statistical analysis Data are expressed as mean ± standard error (SE) values. The 
significance of difference in mean values was determined using two-way analysis of  
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Table 2.1. List of primers 
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varience (ANOVA) with Newman-Keuls and Games-Howell tests for post hoc analysis 
and Student’s t test where applicable. The statistical significance was set at P <0.05 value. 
2.4 Results 
Chronic feeding of HFD in MIL10 mice Starting at ~6-7 weeks of age, male MIL10 and WT 
mice were fed with chow diet or HFD ad libitum for 16 weeks. At the end of the feeding 
period, all mice were age-matched at the time of metabolic studies. MIL10 and WT mice 
showed similar body weights on chow diet, and after 16 weeks of HFD, both groups of 
mice became obese with comparable increases in body weights (Fig. 2.1 A). Consistent 
with this, whole-body fat mass, measured using 1H-MRS, was not different between chow-
fed MIL10 and WT mice, and fat mass increased by 3~4-fold after HFD in both groups of 
mice, being lower in MIL10 mice (Fig. 2.1 B). Although whole-body lean mass was 
statistically different between the groups on chow diet (25.1±0.3 in WT mice vs. 23.5±0.6 
in MIL10 mice; P=0.03), this difference of 1.5 g of lean mass is within the range of 
variability for the lean mass of C57BL/6 mice. Whole body lean mass measurements after 
HFD did not differ between groups (Fig. 2.1 C). Metabolic cage analysis showed no 
significant difference in daily food intake, VO2 consumption, and physical activity values 
between MIL10 and WT mice after 16 weeks of HFD (Fig. 2.2). 
MIL10 mice are protected from HFD-induced insulin resistance Basal glucose levels 
increased after 16 weeks of HFD in both groups of mice, and plasma insulin levels were 
also elevated by more than 6-fold in both groups of mice after HFD (Fig. 2.1 D&E).  To 
determine the effects on whole-body glucose metabolism, a 2-hr hyperinsulinemic-
euglycemic clamp was conducted in awake mice. During clamp, plasma glucose levels  
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Figure 2.1 Metabolic profiles of mice with muscle-specific IL-10-overexpression (M
IL10
) 
and WT mice on standard chow and after 16 weeks of an HFD. A: Body weight. B: Whole 
body fat and C: Whole body lean mass measured using 
1
H-MRS. D, E: Basal plasma 
glucose and insulin levels following overnight fast (~17 hrs). Values are means ± SE for 6 
mice in each group. *P<0.05. 
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Fig 2.2 A 72-hour metabolic cage measurement in M
IL10
 and WT mice on long term HFD 
feeding. A: Oxygen consumption rates B: Daily food intake and C: Hourly physical activity 
of M
IL10
 and WT mice on 16 weeks of HFD. Values are means ± SE for 6 mice in each 
group. 
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were maintained at euglycemia (~7 mM), and plasma insulin levels were raised to ~130 
pM and ~230 pM in both groups of chow and HFD-fed mice, respectively (Fig. 2.3 A&B). 
The WT mice developed insulin resistance after 16 weeks of HFD as shown by a 
~60% decrease in glucose infusion rates during clamp compared to the level in chow-fed 
WT mice (Fig. 2.3 C). Although glucose infusion rates also decreased in the MIL10 mice 
after HFD, the glucose infusion rates in the HFD-fed MIL10 mice were significantly higher 
than HFD-fed WT mice (Fig. 2.3 C). Radioactive isotope labeling data during the clamp 
showed significantly increased whole-body glucose turnover in the HFD-fed MIL10 mice 
compared to the HFD-fed WT mice (Fig. 2.3 D), indicating that the MIL10 mice were more 
insulin sensitive than WT mice after 16 weeks of HFD. 
Increased insulin sensitivity in HFD-fed MIL10 mice was largely due to a 30% 
increase in glucose uptake in skeletal muscle (quadriceps) (Fig. 2.3 E). Insulin-stimulated 
glucose uptake in gastrocnemius muscle also increased in HFD-fed MIL10 mice compared 
to that in HFD-fed WT mice, this difference did not reach a statistical significance (Fig. 
2.3 F). To further examine muscle insulin action, we performed Western blotting using 
skeletal muscle to assess insulin signaling and found that Ser-473 phosphorylation of Akt 
did not differ between WT and MIL10 mice on chow diet, consistent with comparable 
muscle glucose uptake in these mice (Fig. 2.4 A). After 16 weeks of an HFD, muscle Akt 
phosphorylation was decreased by ~70% in WT mice (P=0.1), and muscle Akt 
phosphorylation tended to be higher in HFD-fed MIL10 mice than in HFD-fed WT mice 
(Fig. 2.5 A). H&E stained sections of skeletal muscle from WT and MIL10 mice showed no 
obvious anomaly in the overall structure (Fig. 2.5 B). Additionally, intramuscular  
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Figure 2.3 A 2-hour hyperinsulinemic-euglycemic clamp in awake WT and M
IL10
 mice 
after 16 weeks of HFD or chow diet to assess insulin sensitivity. A, B: Plasma glucose and 
insulin levels during the clamps. C: Steady-state glucose infusion rates during clamps. D: 
Whole body glucose turnover. E, F: Insulin-stimulated glucose uptake in skeletal muscle 
(quadriceps and gastrocnemius). Values are means ± SE for 6 mice in each group. *P<0.05. 
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triglyceride levels tended to be elevated in chow-fed MIL10 mice as compared to the levels 
in chow-fed WT mice (Fig. 2.5 C). After the HFD, intramuscular triglyceride levels were 
comparable between MIL10 and WT mice. The local IL-10 mRNA levels in skeletal muscle 
were approximately 2-fold higher in HFD-fed MIL10 than in HFD-fed WT (Fig. 2.5 D). 
Obesity-mediated inflammation in skeletal muscle is attenuated in MIL10 mice We 
have previously shown that inflammation develops in skeletal muscle after 3 weeks of 
HFD, and that this local inflammation may be causally associated with insulin resistance 
[93]. To that end, we assessed inflammation profile in skeletal muscle by performing qRT-
PCR using samples obtained from HFD-fed MIL10 and WT mice. Skeletal muscle mRNA 
levels of F4/80 and CD68, as markers of macrophage infiltration, were decreased 
significantly in HFD-fed MIL10 mice as compared to HFD-fed WT mice (Fig. 2.6 A&B). 
Muscle MCP-1 mRNA levels also decreased in HFD-fed MIL10 mice (Fig. 2.6 C).   Using 
Luminex analysis, we found that local levels of IFN-γ, IL-1α and IL-6 were increased by 
2- to 4-fold in skeletal muscle samples from WT mice after 16 weeks of HFD (Fig. 2.6 D-
F). In contrast, muscle samples from HFD-fed MIL10 mice showed completely normal 
levels of IFN-γ, IL-1α and IL-6 indicating that muscle IL-10 overexpression protected 
against diet-induced inflammation in skeletal muscle (Fig. 2.6 D-F). We did not observe a 
difference in circulating IL-10 levels in plasma (Fig 2.4 B).  Plasma levels of IL-6 were not 
significantly different between WT and MIL10 mice on chow or HFD. Plasma IL-1α levels 
tended to increase by more than 2-fold in WT mice after 16 weeks of HFD, whereas they 
were not significantly affected by HFD in MIL10 mice. (Fig. 2.4 C&D). 
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Fig. 2.4 A: Insulin-stimulated Akt phosphorylation of chow-fed WT and M
IL10
 mice 
quadriceps muscles. B, C, D: Plasma IL-10, IL-6 and IL-1α levels of same WT and M
IL10
 
mice measured after 16 weeks of HFD (n=5-6/group). E, F: Liver CD68 and F4/80 
macrophage marker mRNA levels in chow and HFD-fed WT and M
IL10
 mice (n=5-
6/group).  
 
 
 
 
 
 
56 
 
 
 
 
 
Figure 2.5 Insulin signaling, muscle morphology and triglyceride and IL-10 levels in 
skeletal muscle. A: Insulin-stimulated Akt phosphorylation in quadriceps muscle. B: H&E 
staining of gastrocnemius muscles. C: Intramuscular triglyceride content (quadriceps) (n= 
3-5/group). D: IL-10 mRNA levels in gastrocnemius muscles measured by quantitative RT-
PCR (n= 4-5/group). Values are means ± SE for each group. *P<0.05. 
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Figure 2.6 Local inflammation in skeletal muscles of M
IL10 
and WT mice after 16 weeks 
of chow or HFD. A-C: F4/80, CD68, and chemokine MCP-1 mRNA levels in quadriceps 
muscles of HFD-fed M
IL10 
and WT mice as measured by qRT-PCR (n=3-5/group). D-F: 
IFN-γ, IL-1α, and IL-6 (F) levels (n=6/group). Values are means ± SE for each group. 
*P<0.05. 
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Obesity-mediated inflammation and insulin resistance in adipose tissue and liver 
Insulin-stimulated glucose uptake in white and brown adipose tissues (BAT) did not differ 
between chow-fed WT and MIL10 mice, and HFD caused insulin resistance in adipose 
tissues in both groups of mice (Fig. 2.7 A&B). mRNA levels of the macrophage markers 
F4/80 and CD68 also increased in WAT by chronic HFD feeding but were not different 
between HFD-fed WT and MIL10 mice (Fig. 2.7 C&D). 
Basal HGP level did not differ between WT and MIL10 mice on chow or HFD (Fig. 
2.8 A). During the clamp, insulin decreased HGP in both chow-fed WT and MIL10 mice 
(Fig. 2.8 B). HFD-fed WT mice developed insulin resistance in liver as indicated by 
increased clamp HGP, but HFD-fed MIL10 mice showed lower clamp HGP than HFD-fed 
WT mice (Fig. 2. 8B). Western blot analysis showed that neither phospho-Akt nor total 
Akt protein levels were altered between WT and MIL10 mice on chow or HFD (Fig. 2.8 C). 
However, liver mRNA levels of G6Pase and phosphoenolpyruvate carboxykinase 
(PEPCK) tended to be lower in HFD-fed MIL10 mice than HFD-fed WT mice (Fig. 2.8 
D&E). mRNA levels of macrophage markers CD68 and F4/80 mRNA levels in liver were 
not significantly altered in HFD-fed MIL10 mice, indicating that local inflammation was 
selectively suppressed in skeletal muscle (Fig. 2.4 E&F).  
IL-10 expressing leptin-deficient mice are protected from insulin resistance Recent 
studies have shown deleterious effects of HFD on the intestinal epithelium and the role of 
gut microbes on obesity-mediated inflammation [378].  Thus, we have generated muscle-
selective IL-10 expressing spontaneously obese mice by cross-breeding MIL10 mice with 
heterozygous leptin-deficient ob/+ mice. The offspring from this cross was further mated  
 
 
59 
 
 
 
 
Figure 2.7 Insulin-stimulated glucose uptake and inflammation in adipose tissues. A, B: 
Insulin-stimulated glucose uptake in white (epidydimal) and brown (intrascapular) adipose 
tissues in WT and M
IL10 
mice fed chow or HFD. (n=4-7/group). C, D: F4/80 and CD68 
mRNA levels in WAT of WT and M
IL10 
mice fed chow or HFD (n=5-6/group). Values are 
means ± SE for each group. *P<0.05. 
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Figure 2.8 Hepatic glucose metabolism and insulin signaling in WT and M
IL10 
mice fed 
chow or HFD for 16 weeks. A: Basal hepatic glucose production. B: Clamp hepatic glucose 
production (n=5-6/group). C: Insulin-stimulated Akt phosphorylation in liver. D, E: Liver 
G6Pase and PEPCK mRNA levels (n=4-6/group). Values are means ± SE for each group. 
*P<0.05. 
 
 
 
 
 
 
61 
 
to obtain MCK-IL10ob/ob mice.  As expected, ob/ob mice became obese spontaneously on 
chow diet, and by 16 weeks of age, whole-body fat mass accounted for more than 50% of 
body weight in ob/ob mice (Fig. 2.9 A&B).  MCK-IL10ob/ob mice also became 
spontaneously obese on chow diet and reached a comparable degree of obesity to ob/ob 
mice at 16 weeks of age (Fig. 2.9 A&B). Basal plasma glucose and fatty acids levels were 
similar in both groups of mice (Fig. 2.9 C & Fig. 2.10 A). A 3-day metabolic cage analysis 
showed that daily food intake and physical activity did not differ between groups (Fig. 2.9 
D&E). In contrast, MCK-IL10ob/ob mice showed a modest but significant increase in energy 
expenditure that was largely due to elevated VO2 consumption rates selectively at night 
cycle as compared to ob/ob mice (Fig. 2.9 F&G). 
Hyperinsulinemic-euglycemic clamp study showed a significantly increased 
whole-body glucose turnover in MCK-IL10ob/ob mice as compared to that in ob/ob mice, 
suggesting increased insulin sensitivity in these mice (Fig. 2.11 A). Consistent with this 
notion, insulin-stimulated glucose uptake in skeletal muscle tended to increase in MCK-
IL10ob/ob mice compared to that in ob/ob mice although this difference did not reach a 
statistical significance (Fig. 2.11 B). Glucose uptake in WAT and hepatic insulin action did 
not differ between groups (Fig. 2.11 C&D). 
Mice lacking muscle IL-10 signaling are insulin resistant after HFD To determine the 
cell type responsible for the downstream effects of IL-10, we have generated mice with 
muscle-specific ablation of IL-10 receptor (M-IL10R-/-) (Fig. 2.10 B&C). Male M-IL10R-
/- mice and MCK-Cre mice (as controls; WT) were fed HFD and chow diet ad libitum 
starting at 7 weeks of age. Metabolic studies were performed after 6 weeks of HFD 
 
 
62 
 
 
 
Figure 2.9 Metabolic effects of muscle-specific IL-10 overexpression in leptin-deficient 
ob/ob mice (MCK-IL10
ob/ob
). A-C: Body weight, whole-body fat mass using 1H-MRS, and 
fasting glucose levels were measured from 7 MCK-IL10
ob/ob
 mice and 11 ob/ob mice. D-
G: Daily food intake, physical activity, energy expenditure, and average of hourly VO2 
consumption were measured during a 3-day analysis of metabolic cages in 3 MCK-
IL10
ob/ob
 mice and 4 ob/ob mice. Values are means ± SE for each group. *P<0.05. 
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Fig 2.10 A: Plasma non-esterified FFA levels of ob/ob and MCK-IL10
ob/ob
 mice 
(n=6/group). Genotyping of M-IL10R
-/-
 mice. B: PCR for Cre gene (450bp) C: IL10R LoxP 
PCR (WT band 220 bp floxed band 280 bp). D: Insulin-stimulated gastrocnemius and 
quadriceps glucose uptake levels in chow and HFD-fed WT and M-IL10R
-/-
 mice (n=5-
8/group) and E: Skeletal muscle IL-10 levels in chow and HFD-fed WT and M-IL10R-/- 
mice (n=4-6/group).  
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Figure 2.11 A 2-hour hyperinsulinemic-euglycemic clamp in awake MCK-IL10
ob/ob
 mice 
and ob/ob mice. A: Whole body glucose turnover in MCK-IL10
ob/ob
 (n=7) and ob/ob (n=11) 
mice. B: Insulin-stimulated glucose uptake in skeletal muscle in gastrocnemius and 
quadriceps muscles. C: WAT (epidydimal) glucose uptake in MCK-IL10
ob/ob
 (n=7) and 
ob/ob (n=11) mice. D: Hepatic insulin action reflected as insulin-mediated percent 
suppression of HGP in MCK-IL10
ob/ob
 (n=7) and ob/ob (n=11) mice. Values are means ± 
SE for each group. *P<0.05. 
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and showed that both M-IL10R-/- and WT mice gained similar fat masses after 6 weeks of 
HFD (Fig.2.12 A). Basal glucose levels were higher after HFD in M-IL10R-/- mice than in 
WT mice (Fig. 2.12 B).  During hyperinsulinemic-euglycemic clamp, plasma glucose 
levels were kept at euglycemia (~7 mM) in both groups of mice.  Strikingly, insulin-
stimulated whole-body glucose turnover rates were significantly decreased and glucose 
infusion rates were lower in HFD-fed M-IL10R-/- than HFD-fed WT mice (Fig. 2.12 C&D). 
Hepatic insulin action during clamp did not differ between WT and M-IL10R-/- groups 
under chow and HFD-fed conditions (Fig. 2.12 E). Quadriceps and gastrocnemius muscle 
glucose uptake levels tend to be lower in M-IL10R-/- mice than in WT mice after HFD (Fig. 
2.10 D). Also, local IL-10 levels in skeletal muscle tended to decrease in M-IL10R-/- mice 
as a possible feedback loop of IL-10 signaling. (Fig. 2.10 E). Skeletal muscle mRNA levels 
of F4/80 (macrophage marker) and inflammatory cytokine tumor necrosis factor (TNF)-α 
were significantly increased in WT mice after HFD (Fig. 2.12 F&G). Importantly, HFD-
fed M-IL10R-/- mice showed significant further increases in F4/80, TNFα, IL-6 and IL-1β 
mRNA levels in skeletal muscle as compared to HFD-fed WT mice, indicating that muscle 
deletion of IL-10 receptor exacerbated HFD-induced local inflammation in skeletal muscle 
(Fig. 2.12 F-I). 
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Figure 2.12 Metabolic profile, insulin action, and skeletal muscle inflammation were 
assessed in M-IL10R
-/-
 and WT mice after 6 weeks of HFD or chow diet feeding. A: Whole 
body fat mass measured using 
1
H-MRS. B: Basal glucose levels. C: Glucose infusion rates 
during hyperinsulinemic-euglycemic clamp in awake mice (n=6-11). D: Whole body 
glucose turnover. E: Hepatic insulin action expressed as insulin-mediated percent 
suppression of HGP. F-I: F4/80, TNFα IL-1β and IL-6 mRNA levels in skeletal muscles of 
M-IL10R
-/-
 and WT mice fed chow or HFD (n=4-7/group). Values are means ± SE for each 
group. *P<0.05. 
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2.5 Discussion 
Although adipose tissue macrophage accumulation and inflammation are 
characterized in obesity-mediated insulin resistance, recent studies refute the cause-and-
effect relationship between adipose tissue inflammation and insulin resistance [30, 78, 133, 
369, 371]. Lee et al. have shown that insulin resistance develops in the absence of adipose 
tissue inflammation after 3 days of high-fat feeding [371]. Our recent study also found that 
a short-term weight loss induced by low-calorie diet or exercise improves insulin 
sensitivity without altering adipose tissue inflammation [133]. These findings indicate that 
adipose tissue inflammation develops in obesity, but it may not be causally associated with 
insulin resistance in skeletal muscle, a major organ responsible for glucose disposal. 
Obesity is a state of systemic inflammation, and local inflammation develops in 
multiple organs including skeletal muscle and liver [89, 93].  Importantly, recent studies 
have suggested a direct and causal role of skeletal muscle inflammation and muscle-
derived cytokines in the development of insulin resistance [94, 147, 153, 168, 379, 380]. 
Our previous study has found that after 3 weeks of high-fat feeding, skeletal muscle was 
characterized by inflammation, insulin resistance and reduced glucose metabolism in 
skeletal muscle [93]. Thus, these findings are consistent with a notion that HFD-mediated 
local inflammation in skeletal muscle is causally associated with insulin resistance. 
However, the metabolic and inflammatory processes ongoing in metabolic tissues through 
short-term high-fat feeding may differ from the events following chronic obesity. 
Additionally, chronic obesity models that are better reflecting type 2 diabetes conditions 
potentially involve an increased insult from immune cells and inflammatory signaling in 
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skeletal muscle, adipose tissue and kidney as well as more compromised lipid metabolism 
and inflammation in liver [371, 381, 382]. Therefore, our current study addressed the 
effects of anti-inflammatory cytokine IL-10 under chronically obese conditions induced by 
a 16-week feeding of HFD. Moreover, leptin is known to regulate inflammation and 
immunity with its effects on T cell and macrophage-secreted cytokines [383, 384]. Thus, 
leptin-deficient model sed in current study rules out the effect of leptin on inflammation. 
Our newly generated MCK-IL10ob/ob model also circumvent direct effects of excess dietary 
fatty acid uptake and fatty acid induced inflammation/insulin resistance because these mice 
develop spontaneous obesity on a chow diet.  
To study a more suitable chronic obesity and type 2 diabetes model in our current 
study, we examined the effects of long-term HFD on glucose metabolism and local 
inflammation in MIL10 mice. After 16 weeks of HFD, WT mice became markedly obese 
with a 4-fold increase in whole-body fat mass. Intramuscular levels of IL-6, IFN-γ, and IL-
1α were low in chow-fed mice, as expected, but after 16 weeks of HFD, local cytokine 
levels in skeletal muscle were elevated by 3 to 4-fold in WT mice. Some of these 
inflammatory cytokines may be released by locally infiltrating macrophages and/or 
surrounding adipocytes in skeletal muscle fiber.  IL-6 was previously shown to induce 
insulin resistance by activating STAT3 and increasing intracellular levels of SOCS3, which 
may target insulin signaling proteins for ubiquitin-mediated degradation, causing insulin 
resistance [79, 385].  In contrast, IL-6 has been shown to be released by exercising muscle 
and to promote glucose uptake, this cellular event involves a much higher level of IL-6 
than what is observed in obesity [386]. Furthermore, IL-1α has been shown to inhibit 
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insulin signaling by inducing serine phosphorylation of IRS-1 in adipocytes [387]. 
Consistent with this notion, insulin-stimulated Akt phosphorylation was reduced in the 
skeletal muscle of HFD-fed WT mice, supporting the cause-and-effect relationship 
between HFD-mediated increase in local macrophage and inflammatory cytokines and 
skeletal muscle insulin resistance. 
Despite marked obesity after 16 weeks of HFD, MIL10 mice were significantly more 
insulin sensitive than WT mice, which was largely due to increased insulin signaling and 
glucose metabolism in skeletal muscle. Intramuscular lipid content was also similar 
between WT and MIL10 mice after HFD indicating that suppressing obesity-mediated 
inflammation in skeletal muscle can improve insulin sensitivity without altering 
intramuscular lipid content in obese mice. IL-10 is an anti-inflammatory cytokine 
previously known as “cytokine synthesis inhibiting factor (CSIF)” and produced by many 
immune cell types including CD4-T helper cells and macrophages [255, 307]. Similar to 
other cytokines, such as IL-6 and TNFα, myocytes have also been shown to express IL-10 
and IL-10 receptors [93, 285]. IL-10 suppresses local inflammation by inhibiting synthesis 
and action of pro-inflammatory cytokines including TNFα, IL-1β and IL-6, as well as 
inhibiting macrophage activation [259, 388]. To that end, intramuscular injection of IL-10 
DNA was shown to be effective in suppressing inflammation and preventing autoimmune 
diabetes in mice [299].  Our findings that obesity-mediated increase in IL-6, IFN-γ, and 
IL-1α in skeletal muscle was normalized in MIL10 mice support the anti-inflammatory 
action of IL-10 in these mice. Also, HFD-fed MIL10 mice had decreased levels of 
macrophage marker F4/80 and CD68 as well as reduced MCP-1 mRNA levels. 
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Importantly, these data indicate that improved glucose metabolism in skeletal muscle may 
be due to IL-10 effects to rescue local inflammation following chronic high-fat feeding in 
these mice. Also, inflammation was suppressed only in skeletal muscles in HFD-fed MIL10 
mice; there was no difference in liver and adipose tissue inflammation. Plasma IL-10 levels 
were also not different in HFD-fed MIL10 mice. Furthermore, in contrast to skeletal muscle, 
white and BAT remained insulin resistant after HFD in MIL10 mice, supporting the muscle-
specific expression of IL-10 and its effects on muscle glucose metabolism. However, we 
found that HGP during clamp state was significantly reduced in MIL10 mice as compared 
to WT mice after 16 weeks of HFD, suggesting improved insulin action in liver of HFD-
fed MIL10 mice.  Since IL-10 has been shown to be released by myocytes and its level has 
been shown to modestly increase in circulation [93], IL-10 may also be responsible for 
suppressing gluconeogenesis in these mice. We did not see a difference in liver Akt 
phosphorylation between HFD-fed groups; however, gluconeogenesis gene expression 
levels tended to decrease in MIL10 mice consistent with reduced HGP in these mice.  
Recent studies have shown that HFD with selective composition of fatty acids may 
be directly responsible for systemic inflammation possibly by altering intestinal 
permeability or gut microbe population [378]. We along with others have also suggested 
that obesity-mediated inflammation is due to excess nutrient availability, imbalanced 
nutrient flux and metabolism, and activation of intracellular endoplasmic reticulum and 
oxidative stress [30, 79, 373]. In order to delineate the important question pertaining to the 
source of obesity-mediated inflammation, we determined the effects of IL-10 in 
spontaneously obese mice by cross-breeding MIL10 mice with leptin-deficient ob/ob mice. 
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As expected, IL-10 expressing ob/ob mice (MCK-IL10ob/ob) became profoundly obese 
while on a chow diet with whole-body fat mass accounting for more than 50% of their body 
weight. Despite being markedly obese and having same level of plasma FFA, MCK-
IL10ob/ob mice were more insulin sensitive than ob/ob mice, further demonstrating IL-10’s 
potent insulin–sensitizing effects associated with its anti-inflammatory effect in skeletal 
muscle. Thus, these data indicate that obesity-mediated inflammation and insulin resistance 
in skeletal muscle are not dependent on dietary composition. Our findings suggest that IL-
10’s insulin sensitizing effects are independent of leptin. 
The beneficial effects of IL-10 to protect against obesity-mediated insulin 
resistance may be due to IL-10’s ability to suppress local inflammation and the deleterious 
action of pro-inflammatory cytokines in skeletal muscle. Gao and colleagues have recently 
shown that hydrodynamic delivery of mouse IL-10 protects against the HFD-mediated 
glucose intolerance that was associated with reduced inflammation in adipose tissue. 
However, since IL-10 receptors are expressed in multiple cell types including immune cells 
and myocytes [93, 226], IL-10’s direct action on myocytes cannot be ruled out.  To further 
determine the mechanism of IL-10’s insulin sensitizing effects, we generated mice with 
muscle-specific ablation of IL-10 receptor. Since deletion was specific to IL-10 receptor 
type 1 we excluded only IL-10 signaling not all IL-10 cytokine subfamily members. After 
6 weeks of HFD, M-IL10R-/- mice became more insulin resistant than WT mice, indicating 
that absence of IL-10 signaling in skeletal muscle exacerbated diet-induced insulin 
resistance. Also, mRNA levels of macrophage markers and inflammatory cytokines are 
elevated profoundly in HFD-fed KO mice. These data suggest that IL-10 effects may be 
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mediated by intracellular IL-10 signaling in skeletal muscle. To that end, we have 
previously found that obesity-induced signal to activate local inflammation may involve 
oxidative stress and altered Ca2+ homeostasis in skeletal muscle [389]. Muscle IL-10 levels 
also tended to be lower in M-IL10R-/- mice that might be result of feedback mechanism.  
Thus, IL-10 signaling in myocytes may relieve oxidative stress and block local 
inflammation, resulting in improved glucose metabolism in skeletal muscle. Further studies 
are needed to understand how IL-10 may affect oxidative stress in skeletal muscle. 
In conclusion, our findings demonstrate that obesity due to chronic high-fat feeding 
or leptin deficiency causes local inflammation with marked increases in IL-6, IL-1α, and 
IFN-γ levels in skeletal muscle.  Obesity-mediated muscle inflammation is completely 
attenuated by IL-10, and this anti-inflammatory action of IL-10 protects against muscle 
insulin resistance. Additionally, IL-10 signaling in myocytes may relieve obesity-induced 
oxidative stress and inflammation in skeletal muscle.  Taken together, these results support 
our previous notion that IL-10 may be a potential therapeutic target to treat insulin 
resistance in type 2 diabetes. Though it has short half-life in vivo, local delivery of IL-10 
is safe and may have positive effects in skeletal muscle insulin sensitivity [307]. While the 
eventual clinical application and method of delivery need further investigation, the role of 
IL-10 as an anti-inflammatory and insulin-sensitizing agent may open new doors in type 2 
diabetes research. 
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Chapter III: Interleukin-10 Prevents Aging-Associated Inflammation and Insulin 
Resistance in Skeletal Muscle 
 
 
 
 
 
 
 
 
 
This chapter is in press in the following format: Dagdeviren S, Jung DY, Friedline RH, 
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Craige SM, Kwon JY, Lee KW, Kim JK. Interleukin-10 Prevents Aging-Associated 
Inflammation and Insulin Resistance in Skeletal Muscle. FASEB J. Vol 31 February 2017 
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3.1 Abstract 
Altered energy balance and insulin resistance are important characteristics of aging. 
Skeletal muscle is a major site of disposal, and the role of aging-associated inflammation 
in skeletal muscle insulin resistance remains unclear. To investigate, we examined glucose 
metabolism in 18-month-old transgenic mice with muscle-specific overexpression of anti-
inflammatory cytokine interleukin-10 (MIL10) and wild-type mice during hyperinsulinemic-
euglycemic clamps. Despite similar fat mass and energy balance, aging MIL10 mice were 
protected from aging-associated insulin resistance with significant increases in glucose 
infusion rates, whole-body glucose turnover and skeletal muscle glucose uptake (~60%, 
p<0.05) as compared to age-matched wild-type mice. This protective effect was associated 
with decreased muscle inflammation, but no changes in adipose tissue inflammation in 
aging MIL10 mice. These results demonstrate the importance of skeletal muscle 
inflammation in aging-mediated insulin resistance, and our findings further implicate a 
potential therapeutic role of anti-inflammatory cytokine in the treatment of aging-mediated 
insulin resistance. 
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3.2 Introduction 
Aging is characterized by alterations in metabolism that resemble a physiological 
state of obesity and insulin resistance [44]. Molecular events underlying insulin resistance 
have been extensively studied but the mechanism of aging-associated insulin resistance 
remains poorly understood. 
Adipose tissue inflammation develops in obesity, and macrophages and 
inflammatory cytokines are causally associated with insulin resistance [370]. Aging is also 
associated with a low-grade chronic inflammation state referred to as “inflamm-aging” that 
involves a multitude of inflammation-related events contributing to morbidity and 
mortality [212, 390, 391]. In that regard, circulating levels of inflammatory cytokines are 
shown to be elevated in elderly human subjects, and these aging-associated events are 
observed independent of obesity [392]. Our recent study has also found that aging promotes 
moderate obesity, adipose tissue inflammation, and insulin resistance in mice [391], 
consistent with findings from human subjects. 
Aging-associated inflammation and increased cytokine response may be caused by 
a declining level of IL-10 during aging [226, 290]. IL-10 is an essential cytokine, mainly 
produced by macrophages, and is responsible for suppressing pro-inflammatory response 
in various tissues, including skeletal muscle [307]. IL-10 prevents inflammation by 
suppressing macrophages and blocking the antigen presentation, as well as the release and 
activity of inflammatory cytokines, such as IL-6, TNFα, and IL-1β [226, 393]. Consistent 
with this, IL-10 KO mice showed elevated levels of inflammatory cytokines following LPS 
 
 
76 
 
stimulation, and aging further exacerbated the inflammatory response in these mice [290]. 
Furthermore, IL-10 has a major beneficial impact on common inflammatory diseases such 
as systemic lupus erythematosus, rheumatoid arthritis, chronic inflammatory bowel 
diseases and multiple sclerosis [307]. Therefore, IL-10 can be a suitable 
immunomodulatory candidate for anti-inflammatory therapy against inflammation-
mediated conditions [307]. Interestingly, Hacham et al., have shown that IL-10 expression 
in skeletal muscle is reduced in aging mice [330]. Therefore, we asked the question ‘Can 
supression of local inflammation in muscle by IL-10 prevent muscle insulin resistance?’. 
In that regard, we have previously shown that mice with muscle-selective overexpression 
of IL-10 (MIL10) are protected from diet-induced insulin resistance in skeletal muscle [93, 
172]. So, we hypothesized that anti-inflammatory cytokine IL-10 can prevent inflammation 
and insulin resistance locally in skeletal muscle. Thus, in the current study, we aimed to 
examine the effects of aging on energy balance, inflammation and insulin resistance in 
MIL10 mice. 
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3.3 Materials and Methods 
Animals Male muscle creatine kinase MIL10 mice (13) and WT littermates (C57BL/6J 
background) were studied from young (4 months of age) to aging (18 months of age) 
(n=8/group). All mice were housed in controlled temperature and light/dark cycle with free 
access to a standard chow diet (Prolab Isopro RMH 3000 5P75; St. Louis, MO, USA) and 
water. All animal studies were approved by the Institutional Animal Care and Use 
Committee of the University of Massachusetts Medical School. 
Body composition and in vivo assessment of energy balance Whole body fat and lean 
mass were non-invasively measured using 1H-MRS (Echo-MRI; Echo Medical Systems, 
Houston, TX, USA). Food intake, physical activity, VO2, VCO2, energy expenditure rates, 
and respiratory exchange ratios were measured via indirect calorimetry in specialized 
single-housed metabolic cages (TSE-Systems Inc., Bad Homburg, Germany).  For these 
metabolic cage measurements, acclimatized WT and MIL10 mice at 12, 14, 16 and 18 
months of age were fed a standard chow diet ad libitum at ambient temperature (20-23 oC) 
under a 12-hour light/dark cycle for 72 hours. Data were collected via equipment-
associated software. 
Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity At 18 months of age, 
we conducted a 2-hr hyperinsulinemic-euglycemic clamp to measure insulin action and 
glucose metabolism in awake mice [394]. Briefly, the clamp began with a primed and 
continuous infusion of human insulin (150 mU/kg bolus followed by 2.5 mU/kg/min), and 
20% glucose was infused at variable rates to maintain euglycemia. During the clamp, [3-
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3H]glucose was infused to assess whole-body glucose turnover, and 2-[14C]DG was bolus 
injected at 75 min of clamp to measure glucose uptake in individual organs [394]. 
Biochemical and molecular analysis Plasma glucose levels during clamp were measured 
with a glucose analayzer (Analox, North Yorkshire, UK). Plasma concentrations of [3-
3H]glucose, 2-[14C]DG, and 3H2O were measured as described previously [394]. Tissue 
and serum triglyceride concentrations were measured using triglyceride assay kit (Sigma, 
St. Louis, MO, USA) using plasma and tissue homogenates. Plasma insulin levels were 
determined by ultra-sensitive ELISA kit (ALPCO Diagnostics, Salem, NH, USA). 
For insulin signaling analysis, skeletal muscle samples (gastrocnemius) were 
collected at the end of clamp, and protein lysates were prepared for Western blots using 
rabbit monoclonal p-Akt-Ser473 and Akt-Ser473 antibodies (Cell signaling, Danvers, MA, 
USA) with β-actin as a loading control. Gastrocnemius lysates were also used to measure 
local muscle levels of IL-1β, MCP-1, IL-10 and IFNγ using multiplexed-ELISA assay with 
Luminex 200 Multiplex Bio-Plex 200 System (Millipore, Darmstadt, Germany) using 
MILLIPLEX® MAP kits (Millipore, Billerca, MA). Plasma leptin, resistin, and 
adiponectin levels were also measured with Luminex. Muscle human growth hormone 
(hGH) levels are measured by ELISA in muscle homogenates (Alpco, Salem, NH, USA). 
For qRT-PCR, RNA isolation was performed with homogenized skeletal muscle 
samples (gastrocnemius) and visceral WAT using TRIzol (Life Sciences, Carslbad, CA, 
USA) following manufacturer’s protocols. cDNA was synthesized from 2 µg of total RNA 
by use of Omniscript cDNA synthesis kit (Qiagen, Venlo, Netherlands). cDNA and 
SYBERgreen supermix (Bio-rad, Hercules,CA) was run in Biorad-CFX96 (Hercules, CA) 
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real time system with the listed primers (Table 3.1). Relative gene expression was 
calculated using Bio-rad CFX manager software normalized to the RPL32 housekeeping 
gene. 
Histological analysis Gastrocnemius muscles were extracted freshly and fixed in 10% 
formalin for overnight, and embedded in paraffin blocks. 5 µm sections were cut and 
stained with H&E to be observed under X20 magnification. 
3.3.6 Exercise study Male MIL10 and WT mice at 18 months of age were used for exercise 
study using treadmills (n=4~5/group). After a 30-minute acclimatization period, treadmill 
speed gradually increased every 3 min between 7.5-15.9 m/min until the mouse was 
exhausted and stopped running. The stopping time and total distance were recorded for 
each mouse. 
Statistical analysis Data are expressed as means ± S.E., and differences between groups 
were examined for statistical significance using analysis of co-variant analysis (ANCOVA) 
and 2 or 1-tailed Student’s t test. A probability value of p<0.05 was used as the criterion 
for statistical significance. 
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Table 3.1 List of primers 
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3.4 Results 
Body composition profile in aging mice Longitudinal changes in body composition were 
recorded in male MIL10 and WT mice fed a standard chow diet from 4 to 18 months of age. 
Body weights of MIL10 and WT mice increased gradually over the first 12 months of age 
and plateaued with further aging (Fig. 3.1 A). Whole body lean mass also increased 
gradually with aging in both groups of mice, but between 13 to 16 months of age, MIL10 
mice showed significantly higher lean mass than WT mice (Fig. 3.1 B). Whole body fat 
mass increased more rapidly in MIL10 mice than in WT mice during the first 8 months of 
age, but they were not significantly different with further aging (Fig. 3.1 C). 
Altered energy balance in aging mice Aging-associated changes in energy balance were 
non-invasively assessed with metabolic cages in male MIL10 and WT mice at 12, 14, 16, 
and 18 months of age. Energy expenditure and VO2 rates were significantly elevated in 
MIL10 mice as compared to WT mice at 16 months of age (Fig. 3.2 A and Fig. 3.3 A). VCO2 
rate also tended to be increased in MIL10 mice as compared to WT mice at 16 months of 
age (p=0.07; Fig. 3.3 B). Respiratory exchange ratio did not differ between aging MIL10 and 
WT mice and reflected consumption of chow diet (Fig. 3.2 B). Daily caloric intake was not 
significantly different between aging MIL10 and WT mice (Fig. 3.2 C). We measured 
circulating levels of leptin, a major hormone regulating feeding behavior, and found that 
serum leptin levels were significantly reduced in aging MIL10 mice as compared to aging 
WT mice (Table 3.2). 
We performed qRT-PCR analysis in muscle samples obtained from young (4 months 
of age) and aging (18 months of age) mice to assess mitochondrial metabolic genes.  
 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Body weight and body composition of MIL10 and wild-type (WT) mice between 
4-18 months of age (n=10-12 per group). A) Body weight. B&C) Whole body lean and fat 
masses measured using 1H-MRS. *P < 0.05 vs. WT mice. 
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Figure 3.2 Longitudinal assessment of energy balance using metabolic cages in aging MIL10 
and wild-type (WT) mice (n=6 per group). Data are averaged from a 3-day continuous 
measurement in mice at 12, 14, 16, and 18 months of age. A) Energy expenditure rate. B) 
Respiratory exchange ratio. C) Daily food intake (caloric intake normalized to body 
weight) D) Hourly physical activity. *P < 0.05 vs. WT mice. #P < 0.05 for vs. physical 
activity in WT mice at 12 months of age. 
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Figure 3.3 VO2 rate normalized to lean mass (A), VCO2 rate normalized to lean mass (B), 
and VO2 rate normalized to fat mass (C) in male MIL10 and WT mice at 12, 14, 16, and 18 
months of age. Values are means ± SE for 6 mice per group. *P<0.05 vs. WT mice. 
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Skeletal muscle mRNA levels of uncoupling protein (UCP)3 and succinate dehydrogenase 
were significantly decreased in both aging groups of WT and MIL10 mice when compared 
with young cohorts (Figure 3.4). Expression of citrate synthase in muscle also tended to 
decline in both groups of aging mice vs. young mice (p=0.06; Fig. 3.4 C). There were no 
significant differences in any of the mitochondrial respiration gene expressions between 
aging WT and aging MIL10 mice. 
Physical activity declined with aging and was significantly reduced in WT mice at 
18 months of age compared with the same group of WT mice at 12 months of age (Fig 3.2 
D). In contrast, this aging-associated decline in physical activity was not observed in MIL10 
mice (Fig. 3.2 D). As a result, MIL10 mice showed a tendency for higher activity than WT 
mice at 18 months of age (p=0.06). To determine whether this affects the exercise capacity, 
we performed a treadmill exercise test and found no significant difference between aging 
MIL10 and WT mice in total distance running on treadmill until exhaustion (Fig 3.5 A). 
Although the hGH sequences are not supposed to be translated, we measured muscle levels 
of growth hormone and found no difference between MIL-10 and WT mice (Fig 3.5 B).  
MIL10 mice are protected from aging-mediated insulin resistance Basal glucose 
and insulin levels in overnight-fasted state did not differ between MIL10 and WT mice at 18 
months of age (Table 3.2). A 2-hour hyperinsulinemic-euglycemic clamp was performed 
to measure insulin action and glucose metabolism in awake age-matched MIL10 and WT 
mice at 18 months of age. Steady-state rates of glucose infusion to maintain euglycemia 
during clamp were significantly increased by 60% in aging MIL10 mice vs. aging WT mice  
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Figure 3.4 Skeletal muscle mRNA levels of uncoupling protein (UCP) 3, succinate 
dehydrogenase, and citrate synthase in young (4 months of age) and aging (18 months of 
age) MIL10 and WT mice. Values are means ± SE for 3-4 mice per group. *P<0.05 vs. 
young mice. 
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Metabolic profile in WT vs. aging MIL10 mice 
 Glucose 
(mg/dl) 
Insulin 
(ng/ml) 
Leptin 
(µg/ml) 
Resistin 
(µg/ml) 
Adiponectin 
(µg/ml) 
Triglyeride 
(mg/dl) 
WT 151±4 0.61±0.16 14±2 12±1 13±1 66±3 
MIL10 135±10 0.56±0.15 5±1* 7±1* 10±1 52±3* 
 
Table 3.2 Metabolic profile in aging WT vs. MIL10 mice. Plasma levels of glucose, insulin, 
leptin, resistin, adiponectin, and triglyceride in overnight-fasted WT and MIL10 mice at 18 
months of age (n=3-5/group). Values are means ± SE. *P<0.05 vs. WT mice. 
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(Fig. 3.6 A). Tracer analysis showed that insulin-stimulated whole-body glucose turnover 
rate was also increased by ~60%, and whole-body glycogen synthesis was increased 2-fold 
in aging MIL10 mice (Fig. 3.6 B&C). Whole body glycolysis was not significantly different 
between the groups (Fig. 3.6 D). These data indicate that aging MIL10 mice are more insulin 
sensitive than aging WT mice. 
Increased insulin action in aging MIL10 mice was largely caused by a 70% increase 
in insulin-stimulated glucose uptake in skeletal muscle (gastrocnemius) (Fig. 3.7 A). 
Because intramuscular lipid content is a major determinant of insulin action, we measured 
muscle triglyceride levels. They did not differ between aging MIL10 and WT mice (Fig. 3.7 
B). Muscle insulin signaling was determined with Western blots using antibodies against 
Akt and phospho-Akt. Total Akt protein levels in skeletal muscle did not differ between 
groups, but phospho-Akt levels were increased by more than 2-fold in aging MIL10 mice vs.  
aging WT mice (p=0.05; Fig. 3.7 C). H&E staining showed that there were no obvious 
changes in skeletal muscle morphology between the groups (Fig. 3.7 D). We measured 
circulating hormones and metabolites known to affect insulin action using multiplexed 
Luminex and Cobas analyzer (Roche Diagnostics, Indianapolis, IN, USA), and found 
significant decreases in plasma leptin, resistin and triglyceride levels in aging MIL10 mice 
vs. aging WT mice (Table 3.2). Plasma adiponectin levels did not significantly differ 
between groups. 
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Figure 3.5 (A) Total distance run on treadmill till exhaustion in MIL10 and WT mice at 24 
months of age. Values are means ± SE for 4-5 mice per group. (B) Muscle hGH levels in 
MIL10 and WT mice at 18 months of age. Values are means ± SE for 7 mice per group. 
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Figure 3.6 A 2-hour hyperinsulinemic-euglycemic clamp to assess insulin action and 
glucose metabolism in awake MIL-10 and wild-type (WT) mice at 18 months of age (n=9-
10 per group). A) Steady-state glucose infusion rates during clamps. B) Whole body 
glucose turnover. C) Whole body glycogen synthesis. D) Whole body glycolysis. *P < 0.05 
vs. WT mice. 
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Figure 3.7 Insulin signaling and glucose/lipid metabolism in skeletal muscle of MIL10 and 
wild-type (WT) mice at 18 months of age (n=7-10 per group). A) Insulin-stimulated 
glucose uptake in skeletal muscle (gastrocnemius). B) Intramuscular (quadriceps) 
triglyceride levels. C) Total Akt and insulin-stimulated Akt phosphorylation at Ser473 in 
skeletal muscle (gastrocnemius). D) H&E staining of gastrocnemius muscle. *P < 0.05 vs. 
WT mice. 
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Aging-associated inflammation in skeletal muscle is reduced in MIL10 mice We have 
previously shown that local inflammation develops in skeletal muscle in obesity is causally 
associated with insulin resistance [93]. The qRT-PCR analysis of skeletal muscle samples 
showed that IL-10 mRNA expression was significantly reduced (>70%) with aging in WT 
mice (Fig. 3.8 A), and this is consistent with previous observations in aging humans [395]. 
Muscle IL-10 mRNA level in aging MIL10 mice was significantly increased (2.5-fold) 
compared with that in aging WT mice (Fig. 3.8 B). This finding was associated with 
significant decreases in CD68 (macrophage marker) and IL-6 mRNA levels in aging MIL10 
mice vs. aging WT mice. Expression of TNFα mRNA in skeletal muscle also tended to be 
lower in aging MIL10 mice. These important changes in inflammatory gene expressions 
were further confirmed at the protein levels. Skeletal muscle IL-10 levels were significantly 
higher in aging MIL10 mice than in aging WT mice (Fig. 3.8 C). Local levels of 
inflammatory cytokines (IFN-γ and IL-1β) and chemokine (MCP-1) in skeletal muscles 
were all significantly reduced in aging MIL10 mice vs. aging WT mice (Fig. 3.8 C).  
In contrast to the profound alterations in glucose metabolism and inflammation in 
skeletal muscle, insulin-stimulated glucose uptake in WAT and expression of F4/80 and 
TNFα in adipose tissue did not differ between aging MIL10 and WT mice (Fig. 3.9 A-C). 
Interestingly, glucose metabolism in BAT was significantly increased in aging MIL10 mice 
vs. aging WT mice (Fig. 3.9 D). Insulin-stimulated glucose uptake in the heart was not 
altered in aging MIL10 mice (Fig. 3.9 D). Furthermore, basal and clamp hepatic glucose 
production, hepatic insulin action and intrahepatic triglyceride levels were not significantly  
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Figure 3.8 Skeletal muscle mRNA and protein levels of inflammatory cytokines, 
macrophages, and chemokines in MIL10 and wild-type (WT) mice (n=3-8 per group). A) 
Muscle IL-10 mRNA levels in WT mice at 4 months (Young) and 18 months of age 
(Aging). B) Muscle mRNA levels of IL-10, CD68, IL-6, and TNFα in aging MIL10 and WT 
mice at 18 months of age. C) Muscle protein levels of IL-10, IFN-γ, IL-1β, and MCP-1 in 
aging MIL10 and WT mice at 18 months of age. *P < 0.05 vs. Young WT mice or WT mice. 
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Figure 3.9 Glucose metabolism and inflammation in adipose tissue and heart of aging 
MIL10 and wild-type (WT) mice at 18 months of age. A) Insulin-stimulated glucose uptake 
in WAT (epidydimal) (n=9-10 per group). B) WAT (epidydimal) mRNA levels of F4/80 
and TNFα (n=4-9 per group). C) Insulin-stimulated glucose uptake in BAT (intrascapular) 
(n=9-10/group). D) Insulin-stimulated glucose uptake in heart (n=4-5 per group). *P < 0.05 
vs. WT mice. 
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Figure 3.10 Hepatic glucose production (HGP) and hepatic insulin action during 
hyperinsulinemic-euglycemic clamp in awake MIL10 and wild-type mice at 18 months of 
age (n=9-10 per group). A) Basal HGP. B) Insulin-stimulated HGP during clamp. C) 
Hepatic insulin action expressed as insulin-mediated percent suppression of basal HGP. D) 
Intrahepatic triglyceride levels. *P < 0.05 vs. wild-type mice. 
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altered in MIL10 mice (Fig. 3.10). These data indicate that aging-associated inflammation 
and insulin resistance were selectively attenuated in skeletal muscle of MIL10 mice. 
 
3.5 Discussion 
Metabolic changes during aging are closely related to several prevalent medical 
conditions, such as obesity, insulin resistance, type 2 diabetes, cardiovascular diseases and 
neurodegenerative disorders. We have previously shown that aging promotes modest 
obesity, adipose tissue inflammation and peripheral insulin resistance, and that these aging-
associated disorders are ameliorated in mice with global deletion of protein tyrosine 
phosphatase 1B, a negative regulator of insulin signaling [391]. Because obesity is an 
aging-related phenomenon that is causally associated with insulin resistance, it is difficult 
to delineate the contribution of aging vs. obesity effects on insulin resistance. In that regard, 
our current results demonstrate that aging mice with muscle-selective overexpression of 
IL-10 are more insulin sensitive than aging WT mice with matched adiposity and 
demonstrate that aging-associated insulin resistance can be rescued independent of obesity. 
Our findings also indicate that beneficial effects of IL-10 were caused by reduced local 
inflammation and improved insulin signaling and glucose metabolism in skeletal muscle.  
A preponderance of recent evidence has highlighted the role of adipose tissue in 
obesity-mediated inflammation and insulin resistance and contributed to an “adipocentric” 
view of type 2 diabetes [30, 78, 370]. However, aging-associated inflammation and insulin 
resistance may develop independent of obesity, suggesting that adipose tissue is not the 
primary organ responsible for dysregulated glucose metabolism in aging [392]. Likewise, 
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in our current study, the aging WT mice gained body weight and fat mass minimally from 
4 to 18 months of age and did not reach a pronounced obese state despite developing insulin 
resistance in multiple organs. Energy expenditure tended to decline slightly, whereas 
physical activity was significantly reduced with aging in WT mice, consistent with 
previous findings [362, 396, 397]. However,  both energy expenditure and physical activity 
were markedly elevated in aging MIL10 mice as compared to aging WT mice, suggesting 
that MIL10 mice were more metabolically active. Although we did not find significant 
differences in total distance running on treadmill until exhaustion, other exercise capacities 
may be altered in aging MIL10 mice. 
We have shown that IL-10 overexpression in skeletal muscle prevents HFD-
induced insulin resistance in mice [93]. Our current study demonstrates that muscle-
specific expression of IL-10 also protects against aging-associated insulin resistance, given 
that aging MIL10 mice showed marked increases in whole-body glucose turnover and 
muscle glucose metabolism vs. aging WT mice. This effect was in part caused by increased 
muscle Akt phosphorylation in aging MIL10 mice, supporting the previous notion that 
defects in muscle insulin signaling may underlie aging-associated insulin resistance [391]. 
Although ectopic lipid accumulation is causally related to obesity-mediated defects in 
insulin signaling [398], our findings of comparable intramuscular triglyceride levels in 
MIL10 and WT mice suggest that other aging-associated factors are responsible for affecting 
muscle insulin signaling in aging mice. 
Adipocyte-derived hormones, such as resistin, adiponectin, and leptin, are known 
to modulate insulin action, and their serum levels have been shown to increase with aging 
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[399-402]. Resistin is a negative regulator of insulin sensitivity and has been shown to 
increase HGP and induce hyperglycemia [399, 400]. Aging MIL10 mice showed 
significantly lower plasma resistin levels vs. aging WT mice. However, neither basal HGP 
nor hepatic insulin action was affected in aging MIL10 mice, suggesting minimal effects of 
resistin in this model. In addition, aging MIL10 mice showed significantly lower leptin levels 
than aging WT mice, although both groups had similar fat mass. In that regard, leptin levels 
usually correlate with adiposity, but this relationship has been shown to be affected by 
aging [403]. Last, serum triglyceride levels also increase with aging in both humans and 
animals [404, 405], and aging MIL10 mice had a lower plasma triglyceride level than aging 
WT mice. Thus, aging MIL10 mice had an overall improved metabolic profile vs. aging WT 
mice.  
Previous studies have reported that IL-10 levels and signaling in skeletal muscle 
decrease with aging, and those findings are consistent with our current data showing lower 
IL-10 levels in aging WT mice [330, 406-408]. In contrast, MIL10 mice were protected from 
this aging-associated effect as muscle IL-10 levels remained consistently higher and within 
a physiological range. This increase in IL-10 expression was able to suppress local 
inflammation in skeletal muscle during aging, because macrophage marker (CD68), 
chemokine (MCP-1), and inflammatory cytokines (IL-6, IFN-γ, IL-1β and TNFα) were all 
reduced in aging MIL10 mice. The physiologic role of IL-10 during aging is largely 
unknown. IL-10 polymorphisms were found to be associated with longevity in men [409], 
and global IL-10 KO mice were shown to develop frailty and altered muscle energy 
metabolism [410].  
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It is important to point out that improved insulin sensitivity in aging MIL10 mice is 
a result of selective increase in muscle glucose metabolism without affecting inflammation 
and metabolism in WAT, which is generally a major focus of the “obesity-inflammation-
diabetes” paradigm. However, there was an increase in BAT glucose uptake in aging MIL10 
mice. This increase may be caused by similarities in the metabolic machinery and 
developmental origin between skeletal muscle and brown fat [411] and secondary effects 
of improved muscle insulin action. To that end, myocardial glucose uptake was not affected 
in aging MIL10 mice. Furthermore, liver is an important organ in maintaining glucose 
homeostasis [412], and there were no significant effects of HGP or intrahepatic lipid levels 
in aging MIL10 mice. Although the main source of IL-10 is macrophages [226], several 
studies have shown that IL-10 is expressed in mouse skeletal muscle and myoblasts [285, 
330]. Thus, the profound effects of IL-10 in skeletal muscle may imply a physiologic 
function of IL-10 signaling on muscle inflammation and glucose metabolism. 
As aging-related diseases often involve mitochondrial dysfunction [362, 413-415], 
we also examined muscle mitochondrial oxidative enzyme expressions in aging mice. Both 
WT and MIL10 mice manifested significant decreases in expressions of mitochondrial 
oxidative enzymes in skeletal muscle with aging, and this effect was comparable between 
WT and MIL10 mice. Thus, aging-associated alterations in mitochondrial metabolic genes 
did not presumably play a major role in improved metabolic activity in MIL10 mice. In 
addition, suppression of muscle inflammation was shown to correlate with increased 
muscle function [242], but the aging MIL10 mice did not exhibit obvious improvement in 
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muscle function based on the treadmill exhaustion test. However, future studies examining 
different aspects of muscle function and exercise capacity are clearly warranted. 
In the transgenic construct of MIL10 mouse model the IL-10 sequence to be 
expressed were flanked downstream by a 2.2-kb segment of human growth hormone (hGH) 
sequence. The purpose of the addition of these sequences was to provide 
polyadenylation/termination signals  and to increase transgene expression efficiency; these 
sequences were not to be translated. Even so, we measured the hGH levels in MIL10 and 
WT mice, and found no difference. This was important, because recently some researchers 
suggested that the inserted hGH sequences in some constructs might be translated [416]. If 
growth hormone was to be expressed in skeletal muscle it could effect muscle mass and 
muscle glucose metabolism, because growth hormone regulates the cellular growth and 
excess growth hormone was shown to decrease insulin sensitivity [417]. 
In summary, our results demostrate that IL-10, as an anti-inflammatory 
immunomodulator, attenuates aging-associated inflammation and improves insulin 
signaling and glucose metabolism in skeletal muscle. Also, our findings imply an important 
role of skeletal muscle inflammation in aging-associated insulin resistance and further 
suggest a therapeutic potential of anti-inflammatory modulators in treating insulin 
resistance and metabolic abnormalities during aging. To that end, application of 
recombinant IL-10 in human has turned out to be safe in most of the clinical trials for the 
treatment of autoimmune diseases, neurodegenerative disorders, and several other 
conditions [307, 418, 419].  Thus, IL-10 may be a promising therapeutic agent for the 
prevention of aging-associated decline in muscle glucose metabolism. 
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Chapter IV: The Role of IL-10 in Myogenesis and Maintaining Lean Mass 
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4.1 Abstract 
Obesity exerts pathophysiological effects on multiple organs including the 
musculoskeletal system. In the previous chapters, we have shown that mice with muscle-
specific overexpression of IL-10 (MIL10) are protected from obesity-mediated inflammation 
and insulin resistance in the muscle. Serendipitously, while we were studying the IL-10-
insulin resistance relationship, we found that MIL10 mice showed an increased lean mass 
phenotype compared to the WT mice during chronic high-fat diet (HFD) feeding (P<0.05). 
X-ray computerized tomography scans confirmed that the higher lean mass phenotype was 
due to the higher skeletal muscle mass. IL-10-expressing leptin-deficient ob/ob mice 
(MCK-IL10ob/ob) also developed higher lean mass than ob/ob mice after 8 weeks of age. 
Moreover, aging MIL10 mice similarly showed higher lean mass than WT mice, whereas 
M-IL10R-/- mice had less lean mass than the controls. Therefore, according to our 
observations, we hypothesized that IL-10 may be inducing skeletal muscle mass increase, 
especially during insulin resistant states. To investigate the effects of IL-10 on muscle 
growth, we incubated C2C12 myoblasts with IL-6, IL-10 and IL-10+IL-6 combination. IL-
10 promoted myoblast proliferation but not differentiation. To determine the mechanism, 
the skeletal muscles of 16-week standard chow or HFD-fed WT and MIL10 mice were 
examined. qRT-PCR was performed to measure the expression of growth-associated 
proliferation and differentiation genes in the skeletal muscle. Expressions of proliferative 
myoblast determination protein (MyoD) and myogenic factor 5 (Myf5) genes in skeletal 
muscle were increased by 2 to 5-fold in MIL10 mice, whereas no difference was observed 
between groups in differentiation genes.  Lean mass was found to be correlated with IL-10 
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and MyoD expression levels in the skeletal muscles of the MIL10 mice. Overall, our findings 
suggest that physiological growth of skeletal muscle to support increased body weight may 
be affected by the obesity-induced inflammation and insulin resistance and IL-10-mediated 
suppression of inflammation and insulin resistance restores healthy muscle growth during 
obesity. 
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4.2 Introduction 
Increased fat mass during obesity stimulates muscle growth due to the weight-
bearing effect. In early obesity, muscle and fat masses are correlated with each other [420]. 
Later on, chronic obesity-induced insulin resistance may impair the ability of the skeletal 
muscle to undergo load-induced muscle growth [421]. Moreover, increased insulin levels 
during early obesity due to insulin resistance is another factor that may promote muscle 
growth at the initial stage, since it is known that resting muscle needs insulin to increase in 
size [422]. Total muscle mass in extremities were shown to be significantly associated with 
increased insulin levels in overweight and obese subjects [423]. We hypothesize that after 
morbid obesity during diabetes the muscle cannot compensate the growth anymore, and 
insulin signaling is impaired, so compensatory muscle growth ceases. At the extremely 
obese and insulin resistant state, skeletal muscle also secretes myostatin which stops 
skeletal muscle growth [424, 425]. Since skeletal muscle is the primary glucose uptake site 
in the body [426], increased muscle mass also improves insulin sensitivity as a feedback 
loop [427]. 
One phenomenon occurring in this extremely obese-diabetic phase is the chronic 
low-grade inflammation of the skeletal muscle [93, 147]. Elevated inflammation in the 
skeletal muscle results in decreased insulin signaling and increased insulin resistance [93]. 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that suppresses macrophage 
activation and pro-inflammatory cytokine synthesis and action [226]. We have previously 
shown that anti-inflammatory cytokine IL-10 improved insulin sensitivity in skeletal 
muscles of obese mice [93, 172]. Serendipitously, while studying insulin resistance, we 
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discovered that transgenic MIL10 mice that are overexpressing IL-10 in skeletal muscles had 
higher lean mass than WT mice after long-term HFD. This finding led us to study the 
relation between IL-10 and skeletal muscle growth during insulin resistant states. Thus, we 
asked the question ‘Does IL-10 induce muscle mass increase during insulin resistant 
states?’. To answer this question, we analyzed the muscles of the transgenic animals during 
insulin resistant conditions. 
Myogenesis is regulated by transcription factors called as ‘Myogenic regulatory 
factors’ (MRFs). The four MRFs: -MyoD, Myf5, Myogenin and Mrf4- are the major 
regulators of myoblast growth and differentiation [428]. MyoD and Myf5 are the early 
myoblast proliferation genes and in the absences of MyoD and Myf5 muscle does not 
develop [429]. MyoD is shown to convert fibroblasts into myoblasts and is required for 
adult stem cell function [430, 431]. It is shown to be activated 3 hours after the satellite 
cell activation [432]. Myogenin, on the other hand, is expressed following MyoD, and is 
the major determinant for the myoblast differentiation [430]. Myocyte enhancer factor 2C 
(MEF2C) is another transcription factor that takes place during muscle differentiation [433-
435]. Major muscle catabolism mediator MAFbx ubiquitin ligase degrades MyoD to inhibit 
muscle growth [431]. Skeletal muscle alpha-actin and myosin heavy chain I (MHCI) are 
also fundamental for the control of muscle mass and function since they comprise most of 
the structural and contractile proteins in the skeletal muscle [436, 437]. We hypothesized 
that IL-10 might be affecting the expression of these regulatory genes to increase muscle 
growth. 
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Myoblasts are somite-derived muscle cell progenitors that can differentiate to form 
skeletal muscle myofibers [438]. C2C12 cells are commonly used murine myoblasts to 
study myogenesis [439]. Therefore, in this study, we measured the expression levels of 
myogenic markers after long-term obesity in IL-10-expressing mouse muscles and IL-10 
induced C2C12 myoblasts to investigate the role of IL-10 on proliferation of myocytes and 
muscle tissue growth. Overall, here we show that lean mass correlates with IL-10 and 
MyoD mRNA expressions in MIL10 transgenic mice, suggesting a constructive role for IL-
10 in maintaining muscle mass during extremely obese and insulin resistant states. 
4.3 Materials and Methods 
Animals For the HFD study, 12 week-old MIL10 male transgenic mice with muscle-specific 
overexpression of IL-10 and WT littermates were fed with HFD (55% fat by calories; 
Harlan Teklad TD93075, Madison, WI, USA) or standard chow diet (Labdiet Prolab Isopro 
RMH 3000 5P75, St. Louis, MO, USA) ad libitum for 16 weeks (n=9/group). For 
spontaneous obesity study, leptin-deficient transgenic mice with muscle-specific 
overexpression of IL-10 (MCK-IL10ob/ob) and ob/ob controls were fed with a standard 
chow diet ad libitum for 11 weeks (n=6/group). For the aging group, MIL10 male transgenic 
mice and WT littermates were fed with a standard chow diet for 12 months. For the last 
study, male muscle-specific knock down of IL-10 receptor 1 mice and MCK-Cre controls 
are fed with HFD for 5 weeks. All mice were housed under controlled temperature (23°C) 
and light/dark cycle with free access to food and water. The animal studies were approved 
by the Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School. 
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Lean mass measurements in mice Whole body fat and lean masses were non-invasively 
measured using Echo-MRI (Echo Medical Systems, Houston, TX, USA) weekly or 
monthly. X-ray computerized tomography of mice are performed by The UMMS Small 
Animal Imaging Core Facility. The muscle:fat ratios were calculated according to the 
average densities calculated for skeletal muscle and adipose tissue by Vivoquant 1.22 
program (Invicro, Boston, MA, USA). Muscle wet weights of freshly collected mouse 
muscles were measured on a sensitive balance. 
Biochemical and molecular analysis For qRT-PCR, RNA is isolated from gastrocnemius 
muscle samples using TRIzol (Life Sciences, Carslbad, CA, USA) according to the 
manufacturer’s protocol. cDNA was synthesized from 2 µg of total RNA by use of 
Omniscript cDNA synthesis kit (Qiagen, Venlo, Netherlands). cDNA and SYBRgreen 
supermix (Bio-rad, Hercules, CA, USA) was run in Biorad-CFX96 real time system with 
the listed primers (Table 4.1). Relative mRNA expressions were calculated compared to 
the housekeeping gene.  
Flow cytometric analysis Left quadriceps muscles from anesthetized animals were 
isolated and minced in Dulbecco’s modified Eagle’s Medium (DMEM) (Gibco, Waltham, 
MA, USA) + 5% fetal bovine serum and 0.2% collagenase (Sigma-Aldrich, St Louis, MO, 
USA). They were shaken at 37°C for one hour, passed through a 70-μm filter, and 
centrifuged with a 70/40 Percoll (Sigma-Aldrich, St Louis, MO, USA) gradient to isolate 
mononuclear cells. Cells were counted and resuspended in the same medium. Single-cell 
suspensions were incubated in 2.4G2 hybridoma supernatant to block FcγR binding for 15 
minutes and combined with CD11b, CD11c, F4/80, CD86 and CD206 conjugated 
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antibodies (Ebioscience, San Jose, CA, USA). Cells were fixed in 4% paraformaldehyde 
and then resuspended in fluorescence-activated cell sorting buffer (1× PBS/1.5% 
FCS/0.05% NaN3). Suspensions were analyzed on a Becton Dickinson (Franklin Lakes, 
NJ, USA) LSRII flow cytometer. At least 20,000 events were collected for each sample, 
and data were analyzed using FlowJo software (Treestar, CA, USA). 
Cell culture experiments For proliferation experiment, 1x104 C2C12 mouse myoblast 
cells in DMEM+10% FBS+Pen/Strep medium were seeded as 3 wells per group in 12-well 
plates. 25 ng IL-10, IL-6 or IL-10+IL-6 (Cell signaling, Danver, MA, USA) were added to 
each well daily. No cytokines were added to the negative control. Cells were cultured for 
48 and 72 hours in the growth medium. At the end of 48 and 72 hours, the cells were 
trypsinized and counted twice per well using a hematocytometer. For differentiation 
experiment, 2x106 C2C12 myoblast cells were seeded as 2 well/group into 12-well plates 
in DMEM+10% FBS growth medium and were allowed to reach confluency for 2 days. 
After 90% confluency was reached, medium was changed to differentiation medium (High 
glucose DMEM+2% Horse serum+ Pen/Strep) and10nM insulin and 25 ng IL-10, IL-6, IL-
10+IL-6 or no cytokine were added to each well daily for 3 days except the control wells. 
At day 4, RNAs were isolated with TRIzol (Life Sciences, Carslbad, CA, USA) for cDNA 
synthesis. qRT-PCR was performed as described above. 
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Table 4.1 List of primers 
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4.4 Results 
IL-10 promotes muscle growth in mice MIL10 mice that are overexpressing IL-10 in the 
skeletal muscle and WT littermates were fed with a 55% fat by calorie-diet for 16 weeks. 
During the first weeks of HFD feeding, lean mass of both groups increased with time. But 
after 10 weeks of HFD, WT group lean mass levels began to reach a plateau. Lean mass of 
MIL10 group measured by 3H-MRI were lower than WT group at the beginning. However, 
lean mass of MIL10 mice continued to increase linearly, and after 12 weeks of chronic HFD 
feeding became significantly higher than WT mice (Fig. 4.1 A). Lean mass of chow-fed 
MCK-IL10ob/ob mice also became significantly higher than ob/ob mice by 7 weeks of age 
(Fig. 4.1 B). When chow-fed MIL10 mice gained weight, and started to become insulin 
resistant after 8 months of age, they also showed higher lean mass than WT mice (Fig. 4.1 
C). Last, we fed M-IL10R-/- mice that are lacking IL-10 receptor in skeletal muscles along 
with controls with HFD for 6 weeks to confirm our findings. Confirming our hypothesis, 
M-IL10R-/- mice started to demonstrate lower lean mass phenotype by the first week of 
HFD (Fig. 4.1 D). To verify that higher lean mass measurement by 3H-NMR is reflecting 
the higher skeletal muscle mass, we calculated muscle:fat ratio using X-ray computerized 
tomography. By using the density values of skeletal muscle and fat, we calculated 
muscle:fat ratios in the whole-body, upper, and lower extremities in WT and MIL10 mice 
fed with 16 weeks of HFD (Fig. 4.2). There wasn’t any difference between chow-fed MIL10 
and WT mice. WT-HFD group muscle:fat ratio was decreased compared to the WT-chow 
group as expected. Muscle:fat ratio of the MIL10-HFD mice were almost two-fold higher 
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Figure 4.1 Lean mass phenotypes of IL-10 transgenic and M-IL10R-/- mice. Whole body 
lean masses of A: MIL10 and WT mice on 16 weeks of HFD (n=9) B: MCK-IL10ob/ob and 
ob/ob mice on chow diet (n=6) C: aging MIL10 and WT mice on chow diet (n=20) and D: 
M-IL10R-/- mice on chow diet (n=6-11) as calculated by H
1
-MRI. Values are means ± SE 
in each group. *P<0.05. 
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Figure 4.2 Muscle: fat ratios calculated by X-ray computed tomography of WT and MIL10 
mice. Whole body, upper extremities and lower extremities muscle: fat ratio of WT and 
MIL10 mice on 16 weeks of HFD or chow diet calculated according to densities of the 
scanned tissues. 
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Figure 4.3 Muscle weights of WT and MIL10 mice fed with HFD for 16 weeks. Measured 
wet weights of A: Quadriceps (QD), B: Tibialis anterior (TA) and C: Soleus (SOL) muscles 
of WT and MIL10 mice fed with HFD for 16 weeks (n=3-4). Values are means ± SE in each 
group. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
than WT-HFD mice, agreeing with the higher lean mass phenotype calculated by the MRI. 
We also isolated fresh skeletal muscles to measure their wet weights. Fast-twitch 
quadriceps and tibialis anterior muscles were measured to be slightly higher in HFD-fed 
MIL10 group compared to WT group (Fig. 4.3 A&B). Slow-twitch soleus muscles 
interestingly measured to be slightly less in HFD-fed MIL10 group than WT group (Fig. 4.3 
C). None of the differences reached statistical significance. 
IL-10 increases proliferation but not differentiation of C2C12 myoblasts To 
investigate the direct effect of IL-10 on myoblast proliferation we seeded C2C12 cells in 
culture plates and added IL-10, IL-6, IL-10+IL-6 or no cytokine into the wells daily and 
counted cells after day 2 and 3. When only IL-10 was added, the cell numbers increased 
by 50% during the first 2 days (Fig. 4.4). After day 2, the cell numbers declined. IL-6 didn’t 
cause a significant increase by day 2. The IL-6+IL-10 combination might also have created 
a cytotoxic effect and decreased cell numbers. To inspect the effect of IL-10 on myoblast 
differentiation, we seeded C2C12 myoblasts into plates and differentiated them. After 4 
days of IL-10, IL-6 or IL-10+IL-6 treatment myogenin gene expressions were detected in 
collected cells. All insulin-added, differentiated groups had higher myogenin mRNA 
expression levels compared to the negative control, but there was no significant difference 
between IL-10, IL-6 and IL-10+IL-6 groups (Fig. 4.5).   
IL-10 increases myogenic gene expression in HFD-fed mice To determine the effects of 
IL-10 on myogenic gene expressions in obese mouse muscles; we isolated RNA from 16-
week chow or HFD-fed MIL10 and WT mice. There wasn’t a significant difference between 
chow-fed groups in major myogenic genes MyoD and Myf5 expressions (Fig. 4.6 A&B). 
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Figure 4.4 IL-10 increased proliferation in myoblasts. C2C12 mouse myoblasts are seeded 
and added with IL-10, IL-6 or both cytokines daily and cells are counted after 48 and 72 
hours for each group. Data are shown as fold change in respect to control wells as an 
average of 3 different plates. Values are means ± SE in each group. *P<0.05. 
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Figure 4.5 IL-10 does not affect myoblast differentiation. C2C12 mouse myoblasts are 
differentiated and added with IL-10, IL-6 or both cytokines daily for 3 days and myogenin 
mRNA levels are measured in duplicate wells. Values are means ± SE in each group. 
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Interestingly, there were prominent increases in MyoD and Myf5 mRNA levels in HFD-
fed MIL10 group compared to WT group (Fig. 4.6 A&B). We also measured MAFbx 
ubiquitin ligase expression in the muscles of HFD mice since it degrades MyoD. MAFbx 
mRNA levels tended to be lower in MIL10 group, but it didn’t reach statistical significance 
(Fig. 4.6 C). To confirm the increased MyoD expression in transgenic IL-10 mouse models, 
we also checked MyoD mRNA levels in MCK-IL10ob/ob mice. MCK-IL10ob/ob mice also 
showed higher MyoD expression compared to ob/ob controls in the muscle (Fig. 4.6 D). 
We also measured skeletal muscle alpha-actin and MHCI mRNA expression levels 
to determine muscle structural protein amounts for muscle function. Even though the levels 
were similar, HFD-fed MIL10 groups had slightly higher mRNA levels than WT-HFD mice 
(Fig. 4.6 E&F). We also checked the differentiation markers in the skeletal muscles. There 
was no significant difference in myogenin and MEF2C differentiation marker mRNA 
levels between the groups (Fig. 4.6 G&H). But, there was a trend of increase in WT-HFD 
mice mRNA levels compared to chow-fed WT mice. This increase was not observed in 
HFD-fed MIL10 mice. 
M2 macrophages are more abundant in HFD-fed MIL10 group than WT group To 
identify immune cell frequencies in the skeletal muscles of the HFD-fed mice we 
performed flow cytometry. Activated M1 macrophages that are known to be recruited 
during obesity [156], and pro-inflammatory CD11b+ F4/80+ M1 macrophages had higher 
frequencies in WT-HFD group muscles than MIL10-HFD group in the preliminary study 
(Fig. 4.7). Interestingly, anti-inflammatory M2 macrophage frequencies were higher in the 
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Figure 4.6 mRNA levels of muscle growth genes in WT and MIL10 mice gastrocnemius 
muscles. A: MyoD, B: Myf5 C: MAFbx mRNA levels in WT and MIL10 mice (n=7). D: 
MyoD mRNA levels in ob/ob and MCK-IL10ob/ob mice (n=3). E: MHCI, F: Alpha-actin 
G: Myogenin and H: MEF2C mRNA levels in WT and MIL10 mice (n=3-5). Values are 
means ± SE in each group. *P<0.05.  
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Figure 4.7 Flow cytometry analysis of skeletal muscle immune cell population in 
quadriceps muscles of WT and MIL10 mice fed with HFD for 16 weeks. M1 and M2 
macrophage frequencies detected by flow cytometry in skeletal muscles of each group 
(n=3). Values are means in each group. 
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skeletal muscles of MIL10-HFD group than WT-HFD group suggesting that M2 polarization 
may be occurring in the IL-10 expressing skeletal muscles of MIL10 mice (Fig. 4.7). 
Lean mass is correlated with IL-10 and MyoD expression levels in HFD-fed MIL10 
mice To investigate the association between increased lean mass, MyoD and IL-10 mRNA 
expression levels in the mouse muscles, we performed correlation analysis. MyoD mRNA 
expression levels in the combination of all groups did not have a correlation with lean mass 
(Fig. 4.8 A). When we analyzed only HFD-fed MIL10 group, we observed a strong 
correlation between MIL10 mice lean mass and MyoD and Myf5 mRNA expression levels 
suggesting that lean mass increase was associated with the increased myogenic gene 
expression levels in obese MIL10 mice (Fig. 4.8 B&C). To examine if IL-10 levels have a 
positive effect on lean mass we made correlation graphs of IL-10 mRNA levels and lean 
mass in HFD-fed mice. When we separated WT-HFD and MIL10-HFD groups, we observed 
that there’s no correlation in WT-HFD mice where endogenous IL-10 levels are low. But 
IL-10 levels and lean mass were strongly correlated in MIL10-HFD mice suggesting a dose 
effect of IL-10 in muscle growth (Fig. 4.9). 
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Figure 4.8 Muscle MyoD and Myf5 mRNA expressions are correlated with lean mass in 
HFD fed MIL10 mice. Muscle MyoD mRNA levels versus lean mass in A: Both WT and 
MIL10 mice fed with HFD or chow diet (n=30), B: in MIL10 mice fed HFD (n=8), C: Muscle 
Myf5 mRNA levels versus lean mass in MIL10 mice fed HFD (n=7). 
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Figure 4.9 Muscle IL-10 mRNA expressions are correlated with lean mass in HFD fed 
MIL10 mice. Muscle IL-10 mRNA levels versus lean mass in A: in WT mice fed with HFD, 
B: in MIL10 mice fed with HFD. 
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4.5 Discussion 
IL-10 is a major cytokine responsible for the termination of anti-inflammatory 
responses in tissues [307]. We have previously found that IL-10 has a preventive effect on 
skeletal muscle insulin resistance [93, 172]. While we were studying with skeletal muscle 
IL-10 overexpressing mice, we discovered the constructive effects of IL-10 in maintaining 
muscle mass in obese mice. This study confirms the beneficial effects of IL-10 in muscle 
growth during insulin resistant-obese conditions. 
During natural process of muscle growth, skeletal muscle mass increases with 
elevating body weight to compensate for the additional load [197]. During the state of 
extreme obesity and insulin resistance, linear growth of muscle is ceased, and muscle mass 
reaches a plateau. We hypothesize that this phenomenon might be caused by the increasing 
inflammation in the muscle with obesity [147], increasing insensitivity to insulin which is 
a major growth stimulator, or decreasing Akt signaling for muscle growth.  
A low-state chronic inflammation in the muscles takes place during chronic obesity, 
manifesting itself by increased pro-inflammatory cytokine production and macrophage 
infiltration [93, 133, 147]. The adverse effect of inflammatory cytokines in the skeletal 
muscle growth was previously shown [440-444]. Major pro-inflammatory cytokines TNFα 
and IL-1β activate NF-κB pathway and downregulate major myogenesis proteins including 
MyoD and myogenin [443, 445]. TNFα also blocks IGF-I pathway through JNK signaling 
[338] and decreases protein content [342], and synthesis [446] in myocytes. C2C12 cell 
line that we used in this study is responsive to inflammatory cytokines TNFα and IL-1β in 
myoblast stage, and therefore, is a good model to study myogenesis [447]. The effect of 
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IL-10 to suppress synthesis, release and action of these inflammatory cytokines may be the 
factor restoring the skeletal muscle growth during obesity. 
During insulin-resistant, extremely obese states insulin sensitivity and Akt 
signaling are impaired in skeletal muscle. Insulin is at the same time a major growth 
hormone acting in skeletal muscle growth and preventing muscle protein breakdown [422, 
448, 449]. Akt is also a signaling mediator downstream of the insulin pathway. It is 
important for Akt/mTOR pathway, a key pathway for skeletal muscle hypertrophy in 
muscle [450]. Increased Akt signaling is shown to result in muscle hypertrophy itself 
through the mTOR pathway [117-119]. Researchers also demonstrated that inducible Akt-
dependent muscle hypertrophy in adult mice led to proliferation of the interstitial cells, but 
not satellite cell activation [119]. Akt also phosphorylates forkhead box O (FOXO) proteins 
and decreases the transcription of ubiquitin ligases like MAFbx and MURF-1[120]. We 
have shown that IL-10 expression in the skeletal muscle improved insulin sensitivity and 
Akt signaling during chronic obesity. This may be another factor restoring muscle growth 
during chronic obesity states in mice. This preventive effect of IL-10 in muscle mass loss 
did not only appear in chronic HFD-fed conditions but also in other chronic obesity 
conditions like leptin-deficiency in ob/ob mice. Aging is also associated with changes in 
body composition that lead to a shift toward increased fat mass and decreased muscle mass 
in normal adults [451]. The same effect was observed in the aging mice skeletal muscles. 
Another important point for validation of our observations was showing the opposite effect 
when IL-10 signaling was blocked in the skeletal muscle. HFD-fed mice that are lacking 
insulin receptor in skeletal muscle displayed the opposite phenotype with lower lean mass 
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compared to controls, which supported our hypothesis. Other studies have also found that 
ablation of IL-10 expression in dystrophic mice increased muscle damage in vivo and 
reduced mouse strength, in concordance with our results [282]. 
When exposed to saturated fatty acids muscle cells co-cultured with macrophages 
tend to polarize macrophages towards M1 type which may promote insulin resistance 
[452]. M1 macrophages are known to play an important role in the obesity-mediated 
inflammation [156].  Lower M1 and higher M2 macrophage frequencies in the muscles of 
MIL10 mice were also interesting in the context that it suggests M2 polarization of 
macrophages by IL-10 may also be contributing to the improved muscle growth in mice. 
In another study, researchers suggested that IL-10 does not have a direct effect on 
proliferation or myogenin expression. However, when muscle cells are co-cultured with 
macrophages, IL-10 treatment polarized macrophages to M2 phenotype and M2 
macrophages indorse the initial, proliferative stage of myogenesis which supports our 
hypothesis [355]. 
MyoD and Myf5 are activated in the early stage of muscle formation and they help 
remodeling of the chromatin for further differentiation factors [453]. Myogenin and 
MEF2C, on the other hand, are expressed later and work together for successful 
differentiation of myoblasts into myotubes [454]. To understand which step of muscle 
formation (early myogenesis or myofibril differentiation) IL-10 is promoting, we worked 
with C2C12 myoblast cultures. IL-10 directly increased myoblast proliferation for the first 
2 days but didn’t have an effect on myogenic gene expression in the differentiated 
myotubes. The decrease in the cell numbers after day-2 might be due to cytotoxicity of 
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cytokines or confluency. According to these results, IL-10 seems to be directly affecting 
early stage myogenesis genes. We also observed that some MIL10 mice had a more 
prominent increase in lean mass than their littermates. The correlation graphs that we 
plotted demonstrated that the increase in the lean mass was associated with the increase in 
MyoD expression which also correlated with the amount of IL-10 expressed in the skeletal 
muscles of MIL10 mice that explains this phenomenon. These results suggested that IL-10 
increases muscle mass in a dose-dependent manner.  
Overall, our working model is: during early obesity, skeletal muscle growth is 
induced to compensate for the increased load due to weight-bearing effect. However, in 
extreme obesity and insulin resistance, the healthy environment the growth of muscle is 
disturbed. Muscle cannot respond to growth signals and muscle growth is stopped, even 
though body weight is still increasing. At this level, suppression of inflammation and 
increase in insulin and Akt signaling are restored by the IL-10 expression, which results in 
the continuation of the linear increase of the muscle mass along with the weight gain. These 
findings define the anti-inflammatory IL-10 as a therapeutic target for the healthy 
homeostasis of the muscle mass during insulin resistant states.  
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Figure 4.10 IL-10 overexpression in skeletal muscles of HFD fed mice is protecting mice 
against muscle growth cessation due to insulin resistance in late-stage obesity.  
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Chapter V: Concluding Remarks and Future Directions 
5.1 Concluding Remarks 
Defining the relationship between chronic inflammation and diabetes is essential to 
understand the reasons and mechanisms lying behind the pathology of this disease. As the 
largest insulin-sensitive tissue, glucose metabolism of the skeletal muscle is fundamental 
for the whole-body glucose homeostasis. Our lab, as well as others, pointed out the 
importance of chronic inflammation in the skeletal muscles of insulin resistant subjects. 
Here in this thesis, I investigated the effects of the anti-inflammatory cytokine IL-10 on 
suppressing the chronic obesity- and aging-associated skeletal muscle inflammation and 
insulin resistance. 
In chapters II and III, I reported the positive effects of IL-10 in obesity and aging-
associated inflammation and insulin resistance. Our lab had already shown the preventive 
effect of IL-10 against insulin resistance during short-term HFD feeding. However, the 
consequences of short-term lipid exposition are different than chronic obesity. Researchers 
have shown that different immune cell types and responses are associated with short-term 
and long-term HFD feeding [371, 381]. In my thesis, I investigated the effects of IL-10 in 
a chronically obese and hyperinsulinemic model that mimics the pathology of type 2 
diabetes more realistically. Also, to eliminate the effects of lipid toxicity in the chronic 
obesity model, I generated MCK-IL10ob/ob mouse model. In both studies, local expression 
of IL-10 in the skeletal muscle improved the insulin sensitivity. These results suggested 
that IL-10’s preventive effects were not only against the fatty acid-induced toxicity, but 
also against the chronic obesity-mediated inflammation.  
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Another significant finding of this thesis is that IL-10 can be effective against 
aging-associated insulin resistance. This is the first study to show IL-10’s protective role 
on aging-driven insulin resistance in skeletal muscle. In our model, adiposity of aging MIL10 
and WT mice were comparable. This fact allowed us to differentiate the effects of obesity 
from aging in our experimental setup. Similar to the result of the obesity studies, IL-10 
preserved the muscle insulin sensitivity in aging mice. In both obesity- and aging-
associated insulin-resistant models, IL-10 improved glucose metabolism by suppressing 
the local inflammation as evident by decreased macrophage recruitment and lowered pro-
inflammatory cytokine levels in the skeletal muscle. These data supported the importance 
of skeletal muscle inflammation in insulin resistance. 
Furthermore, using an HFD-fed muscle IL-10 receptor knock out mouse model, I 
have shown that the direct effect of IL-10 on skeletal muscle fibers is important for muscle 
insulin sensitivity. This was the first in vivo study to show that the direct effect of IL-10 
through IL-10 receptor is required to suppress the local inflammation and improve glucose 
metabolism in skeletal muscle. Although we have shown the importance of direct IL-10-
skeletal muscle signaling, the exact metabolic pathway that IL-10 is triggering in skeletal 
muscle fibers is not determined by our studies yet. Therefore, revealing the detailed 
pathway that IL-10 is triggering in skeletal muscle fibers to improve insulin sensitivity is 
a crucial next step for this study.  
The hypothetical schematic representation of the effects of IL-10 that is derived 
from our results is summarized in Figure 5.1. Obesity and aging can trigger M1 
macrophage recruitment and inflammatory cytokine release from these macrophages. 
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These inflammatory cytokines can interfere with insulin signaling in the skeletal muscle 
through inhibition of tyrosine phosphorylation of IRS-I, and activation of stress kinase 
pathways. This phenomenon can cause insulin resistance and hyperinsulinemia in skeletal 
muscles due to the loss of sensitivity to the insulin. IL-10 can decrease these negative 
effects on insulin signaling by suppressing the macrophage recruitment and pro-
inflammatory cytokine release from the macrophages. Also, IL-10 signaling directly on the 
skeletal muscle fibers can activate STAT3/SOCS3 pathway to inhibit inflammatory 
cytokine synthesis from muscles, which would interfere with the insulin signaling 
otherwise. Overall, the local expression of IL-10 in the skeletal muscle can improve muscle 
insulin sensitivity. 
We showed that IL-10 levels decrease with obesity and aging. Contradictory results 
in literature on increased/decreased serum IL-10 levels during obesity and aging [191, 320, 
322, 323, 455-457] may be due to the fact that the regulation of the IL-10 production and 
the different responses from different immune cell type sources are much more complex 
than we think, and that they show different characteristics according to the exact conditions 
triggering them.  
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Figure 5.1 Schematic representation of potential IL-10’s effects on skeletal muscle glucose 
metabolism 
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IL-10 can be synthesized directly from the myocytes, as evident from the IL-10 
secretion in myoblast-only cultures and increased levels of IL-10 release after exercise 
[284, 285]. But we believe the primary sources in our models are M2 macrophages. IL-10 
was suggested to cause M2 polarization in dystrophic and atrophic mouse models 
previously [282, 355]. Also in our pilot study, we saw that IL-10 over-expression in skeletal 
muscle decreased M1 macrophage and increased M2 macrophage frequencies after HFD-
feeding. Since the main source of IL-10 is M2 macrophages, IL-10 levels may increase as 
a positive feedback loop in this model.  
In chapter IV, I defined a novel role for IL-10 to promote and maintain muscle 
growth in insulin resistant conditions in vivo for the first time. Although there were cell 
culture studies and dystrophic mouse models suggesting an active role for IL-10 in muscle 
growth, our study was the first to demonstrate the in vivo effect of IL-10 on muscle mass 
during obesity- and aging-associated insulin resistance to our knowledge. It was an 
intriguing finding that the positive effect of IL-10 on lean mass was just observed in the 
insulin resistant conditions and not during the healthy state. Some possible mechanisms 
are: -increased inflammation may accompany increased insulin resistance and suppressing 
inflammation rescues inflammation-mediated muscle growth cessation and; - increased 
insulin/IGF signaling in the skeletal muscle due to IL-10’s effects on skeletal muscle may 
prevent muscle growth cessation in skeletal muscle. Type 2 macrophage polarization is 
critical for myogenesis after an injury [458]. Although other researchers did not observe 
the proliferative effect of IL-10 directly on myocyte cultures like we observed; they support 
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our finding which IL-10 causes a type 2 macrophage polarization that increases myoblast 
proliferation [355].  
Although we haven’t conducted experiments on them, we can speculate about the 
mechanism of IL-10-mediated muscle growth. For example IL-10 mediated M2 
macrophage polarization may induce myogenin expression [458].  Or IL-10 itself may 
induce Cyclin D1/c-Myc through Jak/STAT3 pathway to trigger muscle cell proliferation 
[459].  Also, IL-10-activated Jak/STAT3 pathway may interact with MyoD to induce 
satellite cell differentiation [460]. Another possibility is the suppression of TNFα by IL-10 
may prevent TNFα-mediated MyoD destabilization [461]. The IL-10-mediated increase in 
Akt signaling may inhibit FOXO pathway too, which induces muscle ubiquitin ligases 
MAFbx and MURF1 to breakdown muscle [462]. Likewise, the IL-10-mediated increase 
in Akt signaling may inhibit GSK3 which inhibits eukaryotic initiation factor (eif)2b that 
induces muscle protein synthesis [463]. Similarly, the IL-10-mediated increase in 
PI3K/Akt signaling may initiate mTOR pathway that increases muscle protein synthesis 
and growth [464].  
Muscle loss was already associated with chronic inflammation during aging in 
several studies [465, 466]. Therefore, suppressing the inflammation specifically in skeletal 
muscle to rescue age-related muscle mass decline in our studies was on the same line with 
the general view. IL-10 global knock out mice was previously defined as a model of 
decreased muscle strength and muscle wasting [328]. So, our study shows that IL-10’s 
effects are local in the skeletal muscle, and endorses IL-10 as a therapeutic agent to prevent 
these muscular deformities. Although several studies tried to deliver IL-10 DNA by 
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hydrodynamic gene delivery, vector viruses and degradable carriers, no successful direct 
targeting of IL-10 into skeletal muscle was observed up to date [302, 334, 467]. In those 
delivery systems, even when it is injected directly into the skeletal muscle, DNA is 
delivered to the other metabolic organs and IL-10 levels increase in circulation. IL-10’s 
half-life is very short, so it needs to be directly delivered to the target organ efficiently. IL-
10 is meant to suppress all inflammatory processes including the natural vital ones, so high 
levels of IL-10 can form a threat to the general physiological homeostasis. A safe, on-target 
delivery strategy is yet to be developed for the therapeutic use of IL-10.  
To sum up, obesity and insulin resistance induce activation of M1 macrophages and 
pro-inflammatory cytokine release. This in return, blocks the insulin sensitivity and the 
linear growth of skeletal muscles. IL-10 protects against the insulin resistance and growth 
cessation in the skeletal muscles by blocking the recruitment and activation of M1 
macrophages, and release and action of pro-inflammatory cytokines (Fig. 5.2). Overall, the 
role of IL-10 in skeletal muscle as an anti-inflammatory agent requires deeper 
understanding and may hold therapeutic potential in future.  
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Figure 5.2 The schematic of effects of IL-10 on skeletal muscle 
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5.2 Experimental Caveats and Alternative Explanations: 
We observed the positive effects of IL-10 on both muscle insulin sensitivity and 
muscle growth. One thing in common in both scenarios is the insulin signaling. If IL-10 
has an effect of improving insulin signaling, this might explain how it can increase both 
insulin sensitivity and insulin-induced growth. However, detailed studies on the IL-10-
insulin pathway interaction should be conducted to give an answer to this question. 
Our current study design did not explore the origin of the increased muscle mass. 
There is another hypothesis suggested by researchers for the IL-10-mediated muscle 
regeneration. Mesangioblasts are stem cells associated with microvasculature walls in the 
skeletal muscle [468]. Researchers suggested that IL-10 by driving mesangioblast 
differentiation to myogenic lineage can promote muscle growth and regeneration [469]. 
The effect of insulin resistance on mesangioblast differentiation and effect of IL-10 can be 
investigated in the future. 
In this project, we focused on the IL-10’s anti-inflammatory effect to suppress 
insulin resistance. Another mechanism that IL-10 can improve glucose metabolism without 
the anti-inflammatory properties of IL-10, is the insulin-independent activation of Akt. IL-
10 through IL-10 receptor is shown to induce PI3K and Akt pathway itself in fibroblasts 
[470], macrophages [471, 472], cardiomyocytes [473, 474] and adipocytes [206]. Even 
though there is no direct evidence that IL-10 can induce PI3K in skeletal muscle fibers yet, 
it is possible that IL-10 might be inducing Akt pathway independent of insulin to improve 
glucose metabolism in muscle.  
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Another caveat in this study is some of the measurements in skeletal muscles were 
performed on post-clamp samples. Given that during clamp there is a long stimulation of 
insulin, the effect of insulin in inflammation should not be avoided [475]. The experiments 
can be repeated with non-clamped samples for confirmation.  
Since insulin goes through trans-endothelial transport before reaching the skeletal 
muscle fiber surface [106, 476], it is possible that IL-10 has an effect on this transport 
process. For example, IL-10 induces the PI3K/Akt pathway which is important for 
endothelial insulin signaling [477]. The current study is unable to differentiate between 
effects of IL-10 directly on muscle fibers or muscle interstitium including endothelial cells. 
In our experiments, we observed that aging MIL10 mice tended to get exhausted 
faster compared to wildtypes. The current study did not examine contraction force or grip 
strength values and sample number was low. Although, our interpretation was due to a 
single parameter, this tendency to get exhausted earlier may be a sign of higher type II 
fibers in the skeletal muscle. Type I fibers in skeletal muscle have an oxidative profile and 
contract slowly [478], whereas type II fibers are more glycolytic and contract faster [479]. 
A high ratio of fast-twitch type II fibers to slow-twitch fibers is good for short-term intense 
exercise but decreases endurance [480, 481]. Type 2 diabetes promotes an increase in type 
II fibers and a decrease in type I fibers [482]. For example, researchers showed that PPARδ 
expression in skeletal muscle caused a fiber type switch to type I fibers, improving 
exhaustion limit and improving the obesity-induced metabolic phenotype in mice [483]. 
Another group showed that PGC-1α knock out animals exhibited a type I to type II fiber 
switch in muscle and reduced endurance capacity [484]. In our primary results, we saw 
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also a slight increase in fast twitch muscles mass (quadriceps and tibialis anterior) and a 
slight decrease in slow twitch muscle mass (soleus) in MIL10 group which agrees with their 
more rapid exhaustion phenotype. These data suggest that IL-10 expression in skeletal 
muscle may not have prevented slow to fast fiber switch, but on the contrary, may have 
enhanced it. Reduced fast twitch muscle fiber size (tibialis anterior) observed in IL-10 KO 
animals also agree with these results [485]. Effects of IL-10 on skeletal muscle fiber type 
switching has not been investigated, suggesting future avenues of study. 
The more rapid exhaustion profile in aging MIL10 mice might also be caused by a 
fuel switch from FFA to glucose. Randle glucose-fatty acid cycle describes the fuel 
selection by muscle and liver [486]. During exhaustive exercise (e.g. running a marathon) 
lipid was found to be the preferred fuel, and utilization of lipid was dependent on plasma 
concentrations of FFA [487]. IL-10 knock out mice were shown to have 75% increased 
free fatty acid levels after fasting suggesting that IL-10 might have a role in decreasing 
plasma FFA levels [488]. We did not measure plasma FFA levels in aging MIL10 mice. 
However, if plasma FFA levels are lower in MIL10 mice, it might cause a more rapid 
exhaustion and a switch from fatty acid to glucose metabolism. Plasma FFA levels should 
also be evaluated in aging MIL10 mice. 
Our study mainly observed the effect of IL-10 on glucose metabolism in insulin-
induced and glucose-infused conditions. However, the glucose uptake of skeletal muscle 
in other states such as during exercise is insulin-independent [99]. Therefore, as a 
limitation, our study has only explained the effects of IL-10 on muscle glucose metabolism 
in post-absorptive insulin-dependent states. It did not include effects of IL-10 in insulin-
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independent glucose uptake. For example, in the endurance exercise study, exhaustion 
limits of aging MIL10 mice tended to be lower compared to wild types. Therefore, it is 
possible that while IL-10 is improving insulin-dependent muscle glucose uptake, it might 
not have a positive effect on contraction induced glucose uptake.  
5.3 Future directions 
In this thesis, I investigated the local effects of IL-10 in skeletal muscle during 
chronic obesity- and aging-induced insulin resistance and muscle growth cessation. Even 
though we have reached some conclusions on the positive effect of IL-10 on muscle 
glucose metabolism and growth, clearly more research is warranted to unravel the exact 
mechanism of IL-10’s actions. 
In chapters II and III, I discussed that IL-10 signaling in skeletal muscle is 
preventive against chronic obesity and aging-mediated insulin resistance in skeletal 
muscle. Our M-IL10R-/- mouse model was important to show that IL-10 directly acts on 
the skeletal muscle fibers through the IL-10 receptor. Now that we have revealed the direct 
effect of IL-10 on the muscle, it is essential to find the signaling pathways that IL-10 
triggers in the muscle fiber. We know that IL-10 induces STAT3/SOCS3 pathway in the 
skeletal muscles of short-term HFD-fed MIL10 mice [93]. It is also important to see whether 
IL-10 signaling in the skeletal muscle is affecting cellular stress pathways like JNK, IKKβ, 
or ROS. HFD-fed M-IL10R-/- mice could be a good model to compare the activation of 
these pathways in KO and WT mice by immunoblotting of phosphorylated proteins.  
Inflammasomes are multi-protein complexes/sensors that control Caspase-1 
activation and induce inflammation [489]. Researchers linked inflammasome activation in 
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the macrophages to diabetes and β cell death recently [490, 491]. Inflammasomes were 
detected in the skeletal muscles of IL-10 KO mouse model which had increased 
inflammation [485]. It might be interesting to test the existence of activated 
inflammasomes in the skeletal muscles of HFD-fed or aged MIL10 and WT mice by 
measuring Caspase-1 cleavage or activity, or NACHT-LRR-PYD domains-containing 
protein 3 (NLRP3) expression levels. 
The direct effect of IL-10 on the skeletal muscle mass of insulin resistant in vivo 
models is also a novel finding of this thesis. Next step is to find the downstream 
mechanisms of IL-10. Following IL-10 induction of skeletal muscle, Akt phosphorylation 
is increased, which we already confirmed in chapter II. Akt/mTOR pathway is one of the 
major growth pathways, and increased insulin signaling and Akt phosphorylation in 
skeletal muscle can directly trigger mTOR pathway to increase muscle mass. To test this 
hypothesis, we can measure p70S6K phosphorylation by immunoblotting, which is a direct 
downstream target of mTOR, in skeletal muscles of HFD-fed MIL10 and M-IL10R-/- mice. 
Another effect of IL-10 on the muscle growth can be its insulin-sensitizing action. 
To test if IL-10 is acting through the insulin/IGF-I pathway to promote muscle growth, we 
can place an osmotic S961 pump onto the mouse, which is a peptide that blocks the insulin 
receptors [492], and then test myogenic gene expressions in the muscles of HFD-fed MIL10, 
M-IL10R-/-  and WT mice. Also, we can inject insulin-like growth factor I (IGF-I) to the 
skeletal muscles of HFD-fed MIL10 and M-IL10R-/- mice acutely and immediately look at 
downstream Akt phosphorylation to see if IL-10 signaling has any effect on IGF-I-
mediated growth mechanism. 
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Since adult muscle fiber precursors (satellite cells) are mostly quiescent after 
maturation, it is hard to study myogenesis in healthy adult mice. To observe the effect of 
IL-10 in muscle generation we need to trigger injury or atrophy in skeletal muscles. To 
investigate the role of IL-10 on muscle regeneration and maintenance, tail suspension of 
obese or aging MIL10 mice (with controls) as a model of induced, reversible atrophy can be 
used in which we analyze myogenesis marker expression profiles. Tail suspension is an 
easy method to apply, and it mimics muscle wasting due to disuse atrophy that is observed 
during immobility and aging [493]. The differentially expressed myogenic genes after the 
mice are reloaded may give us a clue about the effects of IL-10 in promoting muscle mass 
increase.  
Another study to understand the direct effects of IL-10 on the skeletal muscle fibers 
for promoting muscle growth may be crossing the dystrophic mdx mouse model with MIL10 
and M-IL10R-/- mice. Previously Villalta and colleagues showed that crossing mdx mice 
with the global IL-10 knock out mice exacerbated the muscle damage in dystrophic mice 
[282]. Also, they have shown that when mdx mice are treated with IL-10, regeneration 
increased. Since all these effects are systemic, they don’t differentiate the local effects of 
IL-10 in the skeletal muscle. By generating MIL10mdx mice or M-IL10R-/-mdx mice, we can 
test whether IL-10 can influence the pathology of the dystrophy and muscle regeneration 
by its direct local effect on skeletal muscle. We can determine the numbers of satellite cells 
by immunolabeling or flow cytometry. Another quick method of muscle injury to assess 
the effects of IL-10 in muscle regeneration is the freeze-injury of the muscle, where a liquid 
nitrogen cooled rod is pressed onto exposed skeletal muscle several times to generate 
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freeze-thaw cycles of the muscle [494]. We can apply this method to the HFD-fed MIL10 
and in M-IL10R-/- mouse models, then excise the skeletal muscles again to count satellite 
cell numbers and measure myogenic markers. We can also check the prescence of the 
centrally located nuclei to detect newly formed fibers with conventional histological 
staining in the skeletal muscle.  
We performed our proliferation studies in C2C12 cell line. Showing the effect of 
IL-10 on primary myocytes that are directly isolated from MIL10 and in M-IL10R-/- mice is 
also essential to determine whether the proliferation/differentiation phenotype of primary 
myocytes exposed to high or no IL-10 stimulation for a prolonged time has changed. We 
may isolate primary satellite cells by fluorescence-activated cell sorting according to their 
special surface marker profiles and separate them from non-myogenic and differentiated 
cells [495]. Using the original satellite cells isolated from our mouse models, we can 
perform clonal myogenesis assays to assess their colony-forming ability and determine the 
oxygen consumption and glycolysis using extracellular flux analyzer [496].   
Another important thing to determine is the effects of IL-10 on fiber type 
composition/switching in the skeletal muscle. Researchers suggest that skeletal muscle 
fiber type composition is related to the obesity and diabetes and fiber type switching can 
occur due to insulin resistance and aging [497-500].   The frequency of slow-oxidative type 
I fibers and fast-glycolytic type II fibers can be analyzed by simple nicotinamide adenine 
dinucleotide (NAD)H staining in the skeletal muscle cryosections of aged and obese MIL10 
and M-IL10R-/ mice. Also, we can check myosin heavy chain variants MHCI, MHCII with 
immunofluorescence microscopy. We may furthermore test if improved insulin signaling 
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and suppressed inflammation are specific to a particular fiber type. Researchers previously 
showed that slow-twitch muscle fiber proportion correlates with the insulin responsiveness 
in muscles, and high type I-content muscles like soleus are more insulin sensitive and can 
handle more glucose [501-503]. Therefore, it would be interesting to test if IL-10 regulates 
insulin signaling differently in different muscle fiber types. Inflammation in the muscle 
may also be altered due to the dominant fiber type. Inflammatory cytokine release from 
different fiber types showed different patterns in several studies [504, 505]. Chronic 
inflammation was suggested to increase type II muscle fibers in diaphragm muscle [506]. 
So it is possible that elevated inflammatory cytokines in our obese models with or without 
IL-10 expression can show different fiber type compositions in skeletal muscles. A possible 
way to test this is to compare a slow-twitch fiber dominant muscle (ex. soleus) with a fast-
twitch fiber dominant muscle (ex. extensor digitorium longus, tibialis anterior) for 
inflammation and insulin sensitivity in our IL-10 mouse models. We can also look at the 
structure of the skeletal muscles by electron microscopy to see if there is any difference. 
The orientation of the contractile proteins and structure, and the number of mitochondria 
can give us idea about possible effects of IL-10 on muscle structure and oxidative capacity. 
One possible mechanism that IL-10 is helping maintain muscle mass in insulin 
resistant conditions might be a positive effect of IL-10 on muscle activity. It would be 
interesting to test muscle function in MIL10 and M-IL10R-/- mice looking at different 
parameters such as grip-strength, isometric contraction force and exhaustion limits.  
IL-10 KO mouse model showed decreased longevity compared to wild-type mice 
in studies [328]. Therefore it might be interesting to test the longevity in MIL10 mice, and 
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in M-IL10R-/- mouse models. We actually started a pilot study to observe the longevity of 
MIL10 on a chow diet, but the sample size was not enough to do a thorough statistical 
analysis. Assessing longevities of MIL10 and in M-IL10R-/- mouse models in chow and 
HFD-fed conditions and looking at the expressions of the longevity genes like sirtuins 
might be a potential future aim for this study. 
In our pilot study, we found that M2 macrophage markers were higher and M1 
macrophage markers were lower in skeletal muscles of HFD-fed MIL10 mice than WT mice. 
It was suggesting that the polarization of skeletal muscle macrophages towards M2 
phenotype in obesity due to IL-10 stimulation. To further investigate possible polarization 
effects of IL-10 on skeletal muscle resident macrophages we need to confirm M2 
macrophage increase with higher sample numbers. In addition, we may perform qRT-PCR 
for M2 macrophage marker genes such as Arg1, CD206 and CD163 in skeletal muscles to 
strengthen our hypothesis. 
Another thing we can analyze in MIL10 mouse model is the levels of IL-10 receptor 
expression in muscle. We have seen that in M-IL10R-/- mice IL-10 levels decreased due to 
the absence of positive feedback loop. We can test whether IL-10 receptor expression is 
increased in the MIL10 mice to confirm the feedback mechanism. 
Last, we defined IL-10 as a potential therapeutic agent against inflammation-
induced insulin resistance and growth cessation. Under these circumstances, local delivery 
of IL-10 into skeletal muscle is gaining great importance. There are recent studies 
demonstrating delivery of IL-10 DNA by degradable polymer carriers, adeno-associated 
virus or hydrodynamic delivery [302, 334, 467], yet in these studies serum levels of IL-10 
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increase too. Since IL-10 is a powerful immuno-suppressant agent, it might be dangerous 
to increase systemic levels of IL-10. Instead, we should define a method for targeted 
delivery of IL-10 into the skeletal muscle in future. 
Overall in the light of our findings, the next step is to define the mechanism IL-10 
is acting directly on muscle fibers to increase insulin sensitivity and growth and design a 
site-specific delivery method for IL-10 for future applications.  
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